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ABSTRACT 
African Americans are twice as likely as non-Hispanic Whites to develop Alzheimer’s Disease. 
Current approaches to studying Alzheimer’s disease do not include a sufficient minority population 
needed to understand the nature of this disparity. Evidence from epidemiological and cerebrospinal fluid 
biomarker studies suggests that African Americans do indeed represent a unique phenotype of 
Alzheimer’s disease, partly driven by an elevated presence of risk factors. These risk factors include, but 
are not limited to an elevated presence of vascular disease which can manifest in the brain in the form of 
White Matter Hyperintensities (WMH). Functional magnetic resonance imaging is a method of detecting 
brain activity, and has been used to detect neurological changes within Alzheimer’s Disease in the form 
of functional connectivity (FC). FC is a measure of the correlation of activity between brain regions. In 
our first aim, we examined connectivity between a well-studied network, the default mode network and 
how race modifies the relationship between AD biomarkers and connectivity, and whether WMH in this 
network accounts for these racial differences. We found that race does modify the relationship between 
CSF t-Tau, Aβ42, and cognitive performance between the midline core and dorsomedial subsystems, but 
that WMH did not account for these differences. In our second aim, we analyzed connectivity between 
regions not typically associated with AD including the anterior putamen, pre and post central gyri, and 
superior and middle frontal gyri. We found that, independent of race, anterior putamen to pre and post 
central gyri increased as CSF Aβ42 decreased, but the connectivity decreased as regional WMH volume 
increased.  Within African Americans, connectivity between the middle and superior frontal connectivity 
decreased as CSF Aβ42 decreased, and as regional WMH volume increased. This work further 
characterizes the AA dementia profile, and provides novel regions of exploration that may be affected by 
AD. Furthermore, we provide neurological support for the claim that in studies of individuals with 
Alzheimer’s disease, race should be considered as an important factor of interest in analyses.  
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1 INTRODUCTION  
1.1 Purpose of the Study  
African Americans are twice as likely as Caucasians to develop Alzheimer’s disease (AD) in their 
lifetime1. While hypotheses exist to explain this disparity, there is no known mechanism that fully 
accounts for it2. This lack of knowledge may be attributable to the fact that AD studies typically contain 
data collected from upper-middle class NHWs (Non-Hispanic Whites) with lifestyle and genetic 
backgrounds dissimilar to those of African Americans (AAs)3. In order to determine the nature of the 
differences between Caucasians and African Americans with dementia, we must create models that 
consider the multifaceted concept of race. 
 One method of modeling neurological changes in dementia is magnetic resonance imaging 
(MRI)4. Functional neuroimaging (fMRI) can identify changes in brain activity that supplement current 
AD models5. Disease related fMRI changes correlate with AD biomarkers including tau deposition6, 
amyloid levels7, brain atrophy8, and cognitive performance9. The proposed study seeks to identify the 
unique characteristics of the functional imaging profile of African Americans and determine whether 
ischemic neurological damages in the form of white matter hyperintensities account for any observed 
disparities.  
1.2 A Short Discussion of Race 
Before delving into a discussion of the African American phenotype in the context of 
Alzheimer’s Disease, we must first operationalize the concept of race, and how we propose to study it in 
this body of work. For the purposes of this study, race is a self-reported measure of belonging to a 
specific ethno-cultural group, in this case either NHW or African American. Although it may seem to be 
more biologically viable to include only genetic information to determine race, it would exclude relevant 
lifestyle and cultural factors linked to Alzheimer’s disease such as diet, activity levels, and access to 
healthcare10–13. To understand the nature of racial disparities in dementia we will include race as a 
2 
variable in our models, and then unpack factors under the umbrella of race such as genetic risk factors, 
comorbidities, and socio-economic status (SES) to determine the extent to which these factors account for 
that variability attributed to race.  
1.3 Alzheimer’s Disease & Health Disparities 
Over 5 million Americans currently live with Alzheimer’s disease. It is the sixth leading cause of 
death in individuals over 651. Individuals with Alzheimer’s disease will eventually succumb to its effects, 
but usually not without a gradual decline in daily function. This places a tremendous burden not only on 
the individuals with AD, but caregivers and health professionals that must provide support for patients 
during the diseased period of their lives14. Despite these facts, it remains as the only disease within the top 
10 leading causes of death to have no concrete method to slow, prevent or, cure the disease1.  
1.3.1 Racial disparities in AD 
African Americans are twice as likely to develop AD within their lifetime as are NHWs 2. 
Additionally, unique ethnoracial AD profiles have been identified for CSF 2,15, blood proteomic16, 
genetic17, and lifestyle risk factors18. However, the overwhelming majority of data used to create 
diagnostic and progression models of AD are from NHW populations19. Recruitment and study 
participation bias likely results from an interplay between convenient sampling20, and a lack of active 
networking with diverse populations that may be less likely to seek healthcare at early stages of AD21, and 
exhibit more mistrust towards the scientific and medical community22. Analyses that explicitly consider 
race as a variable of interest may not only enable us to uncover the nature of dementia disparities, but 
indicate to the populations of interest that everyone’s unique life experiences and circumstances are 
valued and important to the scientific community, which could increase research participation of minority 
groups23.   
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1.4 Etiology and Clinical Diagnosis of Alzheimer’s disease 
While we do not fully understand the causes of and risk factors for AD, the disease pathology is 
fairly well defined. Alzheimer’s disease is characterized by the presence of two cellular abnormalities, 
amyloid beta plaques, and neurofibrillary (tau) tangles24. A definitive diagnosis of AD can only be given 
after autopsy of the brain25. The presence of neuro-fibrillary tau tangles (NFTs) and Amyloid-beta (Aβ42) 
plaques serves the basis for a post mortem diagnosis of AD, but this diagnosis is obviously not relevant 
for those living with AD. In the clinic, AD dementia is diagnosed using a multi-faceted approach. A 
diagnosis of Alzheimer’s disease usually comes after a consensus among imaging results, cognitive 
testing, clinical interviews, and, rarely, cerebral spinal fluid biomarkers (tau and Aβ42)26–28.  
Tau and Aβ42 can be detected in cerebrospinal fluid (CSF), and can aid in the diagnosis of AD, in 
that if they are present at pathological levels it would support a diagnosis of AD dementia versus another 
type of dementia29–31. Accumulation of Aβ42 is normal in the aging brain, but the molecular composition 
of plaques in AD is unique24. The Amyloid hypothesis implicates the accumulation of Aβ42 as the impetus 
for AD32: i.e.,  Aβ42 plaques accumulate, which then starts a host of cellular inflammatory responses that 
lead to NFTs, which then leads to neuronal degradation and atrophy33. Although it may seem that the 
presence of Aβ42 is pathogenic, we do not know the mechanism by which it is toxic34. Despite its 
widespread acceptance over the last decade, many clinical trials that decrease Aβ42 accumulation have 
failed, discrediting the amyloid hypothesis32. While the proposed study does not directly probe the 
cellular interactions of Aβ42, better characterizing the diverse population of individuals with AD may 
enable researchers to identify similarities in brain pathology that can aid in the refinement of the amyloid 
hypothesis.  
Despite the unanswered questions about Aβ42 toxicity, there is much evidence that tau 
accumulation and migration across the brain has deleterious effects35.  In its normal state, tau is a 
microtubule-associated protein whose function is to stabilize microtubules that maintain cell polarity and 
axonal transport36. In AD, tau is typically hyperphosphorylated, which may block necessary microtubule 
binding sites36. When tau is present, but does not serve to stabilize microtubules, the microtubules 
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disassemble, and tau accumulates in paired helical filaments, forming the classic neurofibrillary tangles 
(NFTs)36. Without the microtubule structure, axonal transport ceases, and the neuron eventually dies. 
Increased tau levels are detectable in the CSF, and CSF t-Tau serves as a better marker of disease 
progression than Aβ42, as it more closely correlates with cognition31,37,38.  
From a cognitive standpoint, memory impairment is the hallmark cognitive sign of Alzheimer’s 
disease, and is typically correlated with CSF biomarkers of AD and hippocampal atrophy39,40. Short term 
memory deficits are commonly reported in individuals that receive a diagnosis of Alzheimer’s Disease. In 
clinical diagnosis, memory complaints that impair with daily function are often sufficient to receive a 
diagnosis of AD40. However, an individual can present with a mixed cognitive profile, with visuospatial 
and executive function deficits as opposed to only memory complaints25–27.  In fact, African Americans 
are more likely to exhibit non-amnestic cognitive profiles than NHWs42.   
Much of the diagnostic process of AD involves ruling out other causes of dementia including 
stroke, vascular dementia, Parkinson’s disease, geriatric depression, etc. While CSF measures and PET 
images have greater specificity for AD, combined with magnetic resonance imaging (MRI), they are 
much more powerful, and MRI has been cited as more stable indicator of neuronal loss than CSF 
markers44. 
1.4.1 Racial Disparities in diagnostic models of AD 
In multiple cohorts, African Americans have lower CSF total tau than NHWs15,45 despite similar 
levels of Aβ42 and similar cognitive function. This may suggest that African Americans exhibit 
pathological processes after amyloid deposition distinct from NHWs. Additional considerations include 
genetic risk factors unique to race. APOE e4 and the ABCA7 alleles occur at increased rates in AAs, and 
confer different risks across races46. ABCA7 confers a greater risk for AD in AAs, and is present at higher 
rates in this population17,47.  Presence of the APOE e4 allele has differential effects on functional 
connectivity according to race48. We will carefully consider these risk genes in our analyses to determine 
whether their presence explains the racial differences we may observe in connectivity to biomarker 
5 
relationships. Furthering our understanding of the observed differential tau and genetic burden in the 
context of additional AD biomarkers may broaden our understanding of Alzheimer’s disease, and allow 
current models to be more generalizable.  
In general, African Americans may exhibit a distinct cognitive profile in the presence of AD. 
African Americans may be less likely to exhibit amnestic profiles (memory impairment), and thus more 
likely to exhibit dysexecutive syndromes and visual spatial impairment. Cognitive decline in the presence 
of AD may occur at a slower rate in African Americans than NHWs49, 29. This distinct cognitive profile 
may contribute to the under-diagnosis of AD in African Americans, as AD diagnosis is biased towards 
memory complaints and rapid decline12. However, standard clinical assessments typically underestimate 
daily function and overestimate cognitive impairment in African Americans50. While the cognitive profile 
of African Americans with AD is well-characterized, we still do not know the cause of the cognitive 
disparities. The measurement tools themselves may not possess the nuanced cultural relevance required to 
address cognitive impairment in minority populations, as they were developed and validated in a 
homogenous Non-Hispanic White population 51,52,53. Given the inaccuracies in cognitive assessment 
within African Americans, when comparing the relationship between cognition and other AD biomarkers, 
we must consider the underlying racial differences and normalize scores appropriately in statistical 
analyses54–56.  
1.5 Functional Neuroimaging 
Neuronal dysfunction can be indirectly measured by changes in blood flow to regions of the brain 
using the Blood Oxygen Level Dependent (BOLD) signal57. This type of imaging, known as functional 
magnetic resonance imaging (fMRI), can detect functional changes in the framework and meaning of 
“functional networks”. Structural changes occur well after cognitive changes can be detected in the 
trajectory of AD. Memory impairment usually begins before the hippocampus has noticeable atrophy, 
suggesting that neuronal dysfunctional precedes atrophy58. Figure 1 shows the progression of Alzheimer’s 
disease, and when specific biomarker changes occur in the context of symptom emergence. This figure 
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indicates the utility of resting state (rs)-fMRI over structural MRI to detect differences between healthy 
aging brains and those that show signs of dementia, and can be utilized throughout the disease spectrum. 
Of note, this figure shows the emergence of tau markers after rs-fMRI changes begin. Because resting 
state measures may not correlate with tau until an individual has reached a particular threshold of 
amyloid, we will analyze tau and resting measures in individuals who have a clinically significant burden 
of amyloid. The following sections will discuss the what is known about the functional profile of 
Alzheimer’s disease.  
 
Figure 1 Timecourse from Preclinical to Clinical AD: Pathophysiology and Imaging. Taken from 
Sheline, et. al., 2013. 
1.5.1 Default Mode Network in Alzheimer’s Disease 
Regions of the brain that exhibit highly correlated (or connected) BOLD single activity are 
known as “functional networks”. The default mode network (DMN) is perhaps the most commonly 
studied functional network, particularly in dementia59. Typically, regions, or nodes, of the default mode 
network include the ventromedial prefrontal cortex, the precuneus, posterior cingulate, and the inferior 
parietal lobule60,61, but others have divided the DMN into distinct functional subsystems62, and others 
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include the hippocampus as part of this network63. In this work, we focus on connectivity measures 
between nodes of the DMN subnetworks.  
Within Alzheimer’s disease, lower connectivity between DMN nodes is the most commonly 
reported fMRI finding58,64. Within AD, connectivity typically decreases over time, and is lower among all 
regions of the DMN65. DMN connectivity also correlates with other AD biomarkers such as CSF Aβ42 
levels, and hippocampal volumes such that as disease burden indicated by these biomarkers increases, 
DMN connectivity decreases45,66. However, DMN results are not consistent across all studies. Some 
studies have identified a spike in connectivity in the early stages of the disease, during a stage known as 
mild cognitive impairment (MCI), and then a gradual decline67,68. Some studies only report a decrease in 
connectivity between anterior and posterior DMN regions, and others indicate widespread DMN 
changes59,63,65,69. The reasons for these discrepancies may be methodological, but it is also possible that 
essential demographic variables, such as race, were not considered in the analysis. Because African 
Americans exhibit a unique phenotype of AD, and functional connectivity of the DMN is a potential a 
biomarker AD, it is important that racial differences in functional connectivity be explored. One aim of 
this work is to explore the correlates of DMN connectivity in individuals with Alzheimer’s disease, and 
examine how race may modify connectivity relationships to other biomarkers.  
1.5.2 Racial Disparities in Functional Connectivity  
Functional connectivity has not been adequately explored in the context of racial differences. 
Most studies that investigate functional connectivity in African Americans either do not report the racial 
makeup of their sample10, or recruit diverse samples, but do not include race as a factor of interest in 
statistical models70,71, or only recruit African Americans72,73,74. We are by no means suggesting that these 
approaches are flawed, but to point out the literature examining racial disparities in functional 
connectivity profiles is essentially non-existent. Indeed, outright study of racial disparities must be 
thoughtfully conducted as it would be easy to utilize these findings to support discriminatory ideologies. 
However, if we are to understand the nature of racial disparities in Alzheimer’s disease, explicitly 
8 
exploring racial differences is crucial. Because of the gap in the literature on this topic, we have looked to 
studies of racial disparities using other AD biomarkers to inform our hypotheses for this work, and we 
hope that these studies begin to fill this hole.  
1.6 The Putamen in Alzheimer’s Disease 
While much of the research in dementia has centered around the DMN, there is evidence that 
regions outside the DMN may be effected by AD pathology, as far as 10 years out from symptom onset75. 
The putamen is region that is susceptible to both vascular disease76,77 and the effects of AD75. This 
phenomenon has been observed in studies of pathology78, positron emission tomography (PET)79, and 
structural MRI75, with little evidence from functional MRI in AD. Unlike the DMN, the putamen and its 
network nodes are responsible for cognitive performance outside memory domains, including executive 
functions, motor coordination, language processing, and visual spatial function80,81. Many individuals, 
including a larger percentage within the AA population50, experience cognitive impairment in these 
domains in addition to memory41. Because the putamen is involved in these non-memory functions, but 
does exhibit vulnerability to AD, examining this region and its functional networks could provide a novel 
therapeutic target for interventions. However, we must first establish whether connectivity metrics within 
putamen networks correlate with known AD biomarkers.  
Functional putamen networks are fairly well defined in the motor-disease literature82,83. 
Tractography and functional connectivity studies have identified the caudate, parts of the thalamus, 
superior frontal gyrus, middle frontal gyrus, and pre-and post-central gyri as regions most structurally and 
functionally connected to the putamen84,83.  The anterior putamen has clear functional divisions on the 
anterior-posterior axis; the anterior putamen (APu) is classically viewed as a an associative region while 
the posterior putamen supports motor function 85.  The APu appears to be more affected by AD than its 
posterior counterpart in structural MRI86,87,88 and atrophy of the APu better correlates with cognitive 
decline75,89.  In this work, we investigate putaminal, specifically APu connectivity to further our 
understanding of the role of the putamen in AD.  Additionally, because the putamen is vulnerable to both 
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AD and vascular disease, we will investigate the role of white matter hyperintensities (WMH) in putamen 
connectivity.  
1.7 White Matter Hyperintensities  
White Matter Hyperintensities are a significant risk factor for subsequent development of dementia, 
and are related to a number of lifestyle and biological factors90. White Matter Hyperintensities (WMHs) 
are damaged areas of periventricular and subcortical white matter that appear hyperintense on T2 
weighted and Fluid Attenuated Inversion Recovery (FLAIR) scans91. Common neuropathological 
explanations of WMH include demyelination and axonal loss, endothelial dysfunction, and glial 
atrophy91. Their prevalence is variable in aging populations, and represent a risk factor for a host of 
neurological and cognitive complaints later in life such as an elevated risk of stroke or developing mild 
cognitive impairment92. Despite the prevalence of WMH in dementia, they are not specific to Alzheimer’s 
Disease92,93. Although WMH are a risk factor for AD, their absence does not rule out AD, and they can 
occur without amyloid and tau pathology94. Lifestyle and biological factors can affect the presence of 
WMHs such that individuals who smoke95, have diabetes96, or cardiovascular disease39 are at an increased 
risk of developing WMHs.  
White matter hyperintensities (WMH) are a common finding in individuals with Alzheimer’s 
disease (AD), but their etiologic role in AD is not well understood.  There is an increasing debate as to 
where amyloid and tau can cause WMH, or whether amyloid and WMH have a synergistic 
relationship98,99. Individuals with WMH typically have cognitive profiles different than those with “pure 
AD”, the former causing generalized, but less severe, cognitive deficits, and the latter causing memory 
impairment 100. However, recent evidence indicates that WMH could emerge independently of vascular 
disease and arise as a direct result of dementia, as an inflammatory response to amyloid beta 
plaques101,102. It is likely that the two pathologies have a synergistic relationship such that presence of 
WMH can increase vulnerability to AD pathology, particularly Aβ42 plaques. In this work, we will 
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examine WMH and their correlation with CSF levels of tau and amyloid to determine whether the two 
AD biomarkers are related, and whether race modifies this relationship.  
Some studies suggest that location of WMH determines whether they are AD related, or a result of 
vascular disease. WMH seem to have greater posterior involvement in individuals with AD, particularly 
in the parietal lobe98,103. Multiple studies have identified that the presence and volume of WMHs is greater 
in individuals with MCI and AD92,98,104. Some purport that WMHs provide a secondary neuronal insult 
that, in the presence of amyloid deposition, is necessary for the generation of AD105. Others cite the 
importance of the location of WMHs as indicative of disease processes, with AD particularly associated 
with posterior periventricular WMHs caused by tau41,42,102. In this work, we will examine the regional 
volume of WMH to determine if WMH in particular brain regions correlate with levels of CSF tau and 
amyloid which would support some type of causal mechanism between AD and WMH, and whether race 
modifies these relationships. 
WMH can influence functional connectivity measures. WMH along tracts that are between grey 
matter regions of interest (ROIs) can influence connectivity, with connectivity decreasing as internodal 
WMH burden increases106,107. This is likely a result of the decline in neurovascular coupling that occurs in 
the presence of general vascular disease, and, more specifically, ischemic damage, of which WMH are a 
symptom108. We have chosen to focus on regions that are typically associated with AD (DMN), and 
regions vulnerable to both AD and vascular disease (putamen networks) to determine if the connectivity 
measures among these regions more strongly correlates with AD biomarkers or WMH to determine the 
nature of the functional connectivity alterations that we may identify.  
1.7.1 Racial Disparities in White Matter Hyperintensities 
WMH volume better predicts cognitive outcomes than hippocampal volumes in African Americans 
with dementia and Alzheimer’s disease49,109–112. One explanation of this disparity is that African 
Americans are more likely than NHWs to exhibit mixed pathology in the presence of AD, particularly 
evidence of cardiovascular disease113, and that it is consideration of these contributing co-morbidities in 
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the presence of AD pathology that predicts cognitive outcomes in this population114. Any functional 
connectivity differences that we identify between races may be attributable to differences between 
regional distribution of  WMHs, as we have identified racial differences in the correlates of WMHs115,116. 
To date, no studies investigating differences between regional WMH volumes and functional connectivity 
in the context of race have been published.  
1.8 Dissertation Aims 
African Americans have a disproportionately high concentration of lifestyle risk factors, and are 
more likely to show mixed AD pathology when compared to NHWs. As previously mentioned, African 
Americans have higher rates of type-2 diabetes, that may have its roots in both genetic and lifestyle 
factors117. They also have higher rates of vascular disease, including atherosclerosis and peripheral 
vascular disease118,119. Both type-2 diabetes and vascular disease are risk factors for Alzheimer’s 
disease120–122. African Americans have a disproportionately high level of environmental and lifetime 
stressors, which contribute to over poorer brain health12. African Americans, on average, experience more 
perceived stress than age and education matched NHWs, and these stressful life events have a greater 
negative impact on cognition123,124. African Americans are more likely to  have a lower socioeconomic 
status, which usually carries with it substandard housing, low education, and unemployment, all of which 
are individual risk factors Alzheimer’s disease125–129. It is difficult to delineate lifestyle from genetic 
factors when individuals with similar genetic backgrounds have similar life experiences and 
surroundings130. However, in our analyses we will include as many of these relevant potential mediators 
as possible, to uncover biological mechanisms that may explain racial differences.  
African Americans have specific genetic risk factors for AD. The APOE e4 allele is more 
common in African Americans, and only one copy of the e4 variant is necessary to confer a greater AD 
risk for African Americans, unlike other races such as NHWs, in which two copies of the e4 allele are 
necessary to increase the risk of AD131,132. This risk is not purely genetic, as studies with African Yoruba 
tribes show that two copies of the allele are required to increase the risk of developing dementia133. The 
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ABCa7 gene is also associated with increased risk of developing Alzheimer’s disease within African 
Americans, but because the presence of the risk allele is highly collinear with race, its effect can only be 
analyzed within race134,17. Most of the studies that focus on these risk alleles logistically correlate the 
presence or absence of AD with presence or absence of one or two risk alleles. While useful in 
determining the whether a gene poses a risk, little is known about the disease mechanism behind the risk 
alleles and the subsequent effect on brain pathology. In our regression models, we will include the 
presence of APOE e4 as a factor, to determine if it is related to structural and functional neuroimaging 
measures.  
The current set of diagnostic criteria may not be applicable to the broad population of individuals 
with AD. Most of the current models of Alzheimer’s disease, and associated diagnostic cutoffs, have been 
generated in a primarily upper-middle class Caucasian population19,135–137. In order to expand current 
models of AD to a wider population, we must recruit individuals from more diverse backgrounds. African 
Americans often do not fit within the established diagnostic criteria, nor do they exhibit the same 
biomarker profile as NHWs12. Lower tau levels, weaker correlation between cognition and the regions of 
the brain most vulnerable to tau, and a higher prevalence of mixed pathology within African Americans 
point to a unique race-specific mechanism and disease trajectory yet to be defined by the scientific and 
medical community. Functional connectivity provides a method of examining neuronal alterations across 
the disease spectrum that can model the dynamic interactions between regions that may more accurately 
reflect cognitive changes, and respond to ischemic damage prevalent in the AA population.  
Chapter 2 includes the analysis for Aim 1a, an analysis of default mode network connectivity and 
an analysis of the role race in connectivity to biomarker relationships in the context of dementia. Chapter 
3 includes analyses for Aim 1b, which includes analysis of functional connectivity of the DMN and its 
subnetworks, and how these measures relate to regional hyperintensities, and the role of race. Chapter 4 
includes both Aims 2 a & b; an analysis of putamen network connectivity, the role of hyperintensities, 
and how race modifies some of these relationships.  
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1.9 Specific Aims 
1.9.1 Aim 1a: Determine the extent to which race modifies the relationship between connectivity of 
the DMN subnetworks and AD biomarkers.  
1.9.2 Aim 1b: Determine the extent to which regional WMH account for racial differences we 
observe in DMN connectivity to biomarker relationships.  
1.9.3 Aim 2a. Determine whether cortico-putamen connectivity correlates with AD biomarkers, and 
whether race modifies these relationships.  
1.9.4 Aim 2b. Determine whether regional WMH relates to connectivity and accounts for any 
observed differences in connectivity to biomarker relationships.  
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2 AIM 1A: RACE MODIFIES DEFAULT MODE CONNECTIVITY IN ALZHEIMER’S 
DISEASE 
Maria B Misiura, M.A. 1,2, J. Christina Howell, B.A.2,  Junjie Wu PhD3, Deqiang Qiu, PhD,3, Monica W. 
Parker, M.D.2, Jessica A.Turner, PhD1, William T Hu, M.D., PhD.2  
1Department of Psychology, Georgia State University. Atlanta, GA 
Departments of 2Neurology and 3Radiology, Emory University. Atlanta, GA 
 
Abstract 
Background: Older African Americans are more likely to develop Alzheimer’s disease (AD) than older 
Caucasians, and this difference cannot be readily explained by cerebrovascular and socioeconomic factors 
alone. We previously showed that mild cognitive impairment and AD dementia were associated with 
attenuated increases in the cerebrospinal fluid (CSF) levels of total and phosphorylated t-Tau in African 
Americans compared to Caucasians, even though there was no difference in beta-amyloid 1-42 level 
between the two races.   
Methods: We extend our work by analyzing early functional magnetic resonance imaging biomarkers of 
the default mode network MRI between older African Americans and Caucasians. We calculated 
connectivity between nodes of the regions belonging to the various default mode network subsystems and 
correlated these imaging biomarkers with non-imaging biomarkers implicated in AD (CSF amyloid, total 
tau, and cognitive performance).  
Results: We found that race modifies the relationship between functional connectivity of default mode 
network subsystems and cognitive performance, tau, and amyloid levels.  
Conclusion: These findings provide further support that race modifies the AD phenotypes downstream 
from cerebral amyloid deposition, and identifies key inter-subsystem connections for deep imaging and 
neuropathologic characterization.  
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2.1 Introduction 
It is not well understood why older African Americans are twice as likely to develop Alzheimer’s 
disease (AD) as older non-Hispanic Caucasian Americans (abbreviated as Caucasian hereafter).140,141  
While vascular disease12,126,142 has been speculated to contribute to the disparities in AD risks, genome-
wide association and clinical studies suggest race/ethnicity (hereafter referred to as race), outside of these 
factors, also modify the molecular pathways implicated in the development and manifestation of AD 
pathology.  For example, the APOE ε4 allele confers lower AD risks for African Americans than 
Caucasians,135,143 the ABCA7 risk allele confers greater AD risks for African Americans than 
Caucasians17, and AD is associated with less amnestic baseline and slower longitudinal decline in African 
Americans than Caucasians on neuropsychological analysis.42  These cohort-level differences may reflect 
intrinsic biological differences between race, lower correlation between clinically-suspected and 
pathologically-confirmed AD (~75% accurate), recruitment bias in one or both races, or a combination of 
these factors27,144.  Data-driven strategies are therefore necessary to provide mechanistic correlates of 
observed race-associated differences to more clearly understand AD disparity. 
One such approach is to use etiologic biomarkers associated with hallmark AD pathology to 
enhance the likelihood that those clinically suspected to have AD indeed have the pathology. We recently 
showed that in a group of older adults with mild cognitive impairment (MCI) or AD dementia, African 
Americans had lower cerebrospinal fluid (CSF) levels of t-Tau-related biomarkers than Caucasians15. This 
is despite similar changes in CSF levels beta-amyloid 1-42 (Aβ42).  We interpreted these findings as 
preliminary evidence for divergent biomarker trajectories and these differences have now been validated 
in one independent cohort in St. Louis and an independent younger cohort in Atlanta 145,146.   
Because we have not identified a difference in atrophy patterns between African Americans and 
Caucasians with AD, we hypothesized that rsfMRI would be a more sensitive approach to identify the 
effect of race on AD-related neurological changes.  We are particularly interested in resting state 
functional connectivity, as alterations in connectivity can be detected well before disease onset147 and 
track disease progression.148   To explore brain changes associated with AD which may differ between 
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races, we analyzed functional connectivity (hereafter referred to as connectivity) in the default mode 
network (DMN) using resting-state functional MRI (rsfMRI). The DMN is considered a potentially useful 
imaging biomarker for AD that is more widely available than amyloid PET65,68,149–152.    
In older adults, the DMN is broadly defined as correlated Blood Oxygen Level Dependent 
(BOLD) signal among the precuneus, posterior cingulate cortex (PCC), the inferior parietal lobule (IPL), 
the ventromedial prefrontal cortex (vmPFC). 68,153  The DMN overlaps with anatomical sites vulnerable to 
amyloid deposition and atrophy in early AD, 154  and reduced connectivity between DMN nodes (intra-
network connectivity) mirrors the stage-wise t-Tau deposition on PET imaging45,155 even before there is 
detectable atrophy.12  The trajectory of AD functional connectivity changes is complex. The 
overwhelming majority of studies examining four DMN nodes reported reduced connectivity in AD 
(dementia),61, 156, 67, 157, 158 with an exception reporting increased connectivity during early MCI.61  
However, few studies used etiologic biomarkers to distinguish between cognitive impairment due to AD, 
psychiatric illness, or cerebrovascular disease159. DMN hyperconnectivity has also been observed in 
asymptomatic APOE ε4 carriers when compared to non-carriers,160, 161 sometimes decades before 
symptom onset.162  DMN connectivity may therefore have different relationships with AD risks 
(including risk genes), pathologic markers, clinical phenotypes, and disease stage, making inclusion of 
etiologic and clinical biomarkers in AD-related DMN analysis critical to ensure the consistency of 
findings.   
As research on the DMN progresses, further fractionation of this complex network has revealed 
synchronous bold activity in regions outside traditional definitions of the DMN.  Core subsystems64 
(dorsomedial, medial temporal lobe, and midline core) have been proposed to each contain key regions 
which work in tandem to support cognitive processes in learning and memory, retrieval of 
autobiographical information, self-referential processes,163, and social processing164. Dividing the DMN 
into its subcomponents has thus far provided more sensitive timelines for disease progression in AD and 
other neurological disorders156. Studies have shown that connectivity within the medial temporal lobe, 
rather than average DMN connectivity between the four core nodes, more consistently relates to cognitive 
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impairment in AD30,148; increases in connectivity within the anterior subsystems during early AD is more 
consistently identified in studies analyzing DMN subsystems34,157; and memory impairment can be 
associated with decreased intra-subsystem connectivity within the medial temporal lobe165 but increased 
connectivity between dorsomedial and midline core subsystems166, 167. 
The vast majority of studies analyze connectivity changes within diagnostic categories of normal 
cognition (NC), MCI, and AD dementia. Given that differences in cognitive impairment between NC and 
MCI and between MCI and AD dementia can sometimes be small, a continuous measure of cognition is 
preferred168,169 especially when it remains controversial whether current diagnostic algorithms are valid in 
African Americans (even with race-adjusted norms)12,49. Thus, we also use a composite measure of 
cognitive performance derived from neuropsychological tests15 to serve as a continuous, rather than 
categorical, measure of disease burden. We hypothesized that race modifies the relationship between 
connectivity and AD-related cognitive impairment, and between connectivity and two CSF AD 
biomarkers (Aβ42170 and t-Tau171).  Furthermore, we specifically tested the generalizability of AD-
associated connectivity changes between DMN nodes and between DMN subsystems to extend the AD 
biomarker phenotype in African Americans.  
2.2 Methods 
Participants  
  This study analyzed previously collected data from a study that recruited self-reported 
Non-Hispanic Whites and African Americans over the age of 65 across the diagnostic spectrum of 
Alzheimer’s disease dementia including individuals with normal cognition (NC), individuals with mild 
cognitive impairment (MCI), and individuals with Alzheimer’s Disease (AD)15.  The study was approved 
by the Emory University Institutional Review Board.  Each participant underwent a detailed interview for 
demographic information, self-reported race (Caucasians of Hispanic or Latino ethnicity were not 
included in this study), vascular risk factors (coronary artery disease, congestive heart failure, atrial 
fibrillation, hypertension, hyperlipidemia, diabetes, suspected transient ischemic attack), other medical 
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comorbidities (e.g., cancer), and medications (e.g., use of angiotensin-converting enzyme inhibitors or 
angiotensin II receptor blockers). Each participant was then assigned a diagnosis according to consensus 
criteria including those for normal cognition (NC), MCI, and AD dementia (global Clinical Dementia 
Rating of 1 or 2.) Cognitively impaired subjects suspected of having a non-AD dementia (vascular, Lewy 
body, and frontotemporal dementia) were excluded.  While our cohort was not age and gender matched 
specifically, we did not find significant differences in age between races or gender (Table 1). As 
previously reported, diabetes and hypertension were more common in African Americans than 
Caucasians, but had lower brain total white matter hyperintensity (WMH) volumes than Caucasians.  
Demographic data in table 1 refer to individuals who passed MRI quality control standards (n=137) as 
described below.   
Cognitive, genetic, and CSF biomarkers 
Neuropsychological analysis was performed as previously described15.  Briefly, each subject 
underwent. Each subject also underwent a detailed neurologic examination and neuropsychological 
analysis for assessment of function in cognitive domains. These included(1) memory (Consortium to 
Establish A Registry for Alzheimer’s Disease word list delayed recall, Brief Visual Memory Test–
Revised [BVMT-R] delayed recall), (2) executive func-tion (Trail Making Test B, reverse digit span 
[RD], Symbol Digit Substitution Test, and letter-guided fluency), (3) language (Boston Naming Test [60 
items], category fluency), and (4) visuospatial function (Judgment of Line Orientation[JOLO], Rey-
Osterrieth complex figure test). With the exception of BVMT-R, JOLO, and RD, subtest Z-scores were 
calculated according to published normative data, adjusting for age, sex, education, and race. Z-scores for 
these three subtests were calculated using the same norms were used in Caucasians, but calculated using 
Atlanta-based, cognitively normal African Americans because published norms generated mean Z-scores 
of >2.  Domain-specific Z-scores were calculated by averaging subtest Z-scores, and Z-scores for the four 
domains were averaged to generate composite cognitive Z-scores. Subjects with MCI and AD dementia 
had lower MMSE and cognitive Z-scores than subjects with NC (p <.01 for all comparisons, Table 1). In 
addition, each subject underwent standardized collection of blood (for APOE and ABCA7 genotyping) and 
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CSF without overnight fasting according to a modified Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) protocol as previously described.34   
MRI acquisition and preprocessing 
  Each subject underwent MRI scanning using a modified ADNI protocol on a 3T scanner 
(Siemens AG) which included a T1-weighted 3D MPRAGE sequence (TR/TI/TE = 1620/950/3msec, flip 
angle = 30o, matrix = 192×256×160, and voxel size = 0.98×0.98×1mm3) and a 6 minute eyes-open resting 
state functional MRI scan (TR/TE = 3000ms/32ms flip angle = 90o, field of view 
(FOV) = 200 × 200 mm2, acquisition matrix = 64 × 64, voxel size = 3.1 × 3.1 × 3.5 mm3, slice = 33, time 
point = 124) at the Emory Center for Systems Imaging. For rsf-MRI, we used the DPABI v4.0.190305 
toolbox to preprocess the image data172 after discarding the first 10 volumes to allow the magnetization to 
approach a dynamic equilibrium, and to allow for more time for our participants to get comfortable inside 
the scanner158,173. Individual echo-planar imaging (EPI) data were slice time corrected. Participants whose 
head motion exceeded 3.0 mm in translation or 3° in rotation were excluded. We further reduced the 
confound of head motion by higher-order regression based on Friston's 24-parameter model 174, and the 
effect of physiological artifacts by covarying signals from CSF space and white matter.175  EPI data were 
normalized to a study specific template generated using the DARTEL algorithm in DPABI that is better 
suited for populations with larger amounts of atrophy than standard normalization to the MNI template.176  
A spatial filter of 6 mm full width at half maximum Gaussian kernel was used. Subsequently, a band pass 
temporal filter (0.01–0.08 Hz) was applied to reduce the low-frequency drifts and high-frequency noise.  
MRI Quality Control  
  To be eligible for this analysis, participants must have had a T1 suitable for use in 
segmentation, as well as a usable resting state scan. To further eliminate confounds from head motion, we 
removed anyone whose mean framewise displacement (MWFD) was 3mm and higher177.  Among 145 
subjects, 8 (5%) had rsf-MRI that did not pass quality control and were excluded from DMN analysis. 
Table 1 displays demographic data only for individuals included in the MRI analysis (n=137), and Table 
2 shows demographic data for individuals not included in the analysis. Compared to those included the 
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analysis, those excluded did not differ significantly in age, gender, diagnosis, or race. There was no 
significant difference in motion according to race or diagnosis.  
Rsf-MRI Independent Component Analysis 
  We used a data driven approach (Independent 
Component Analysis; ICA) using the Group ICA of fMRI Toolbox 
v4.0b (GIFT) to identify large-scale brain networks.178,179 We first 
performed independent components analysis with model-order of 80 
to empirically derive our regions of interest which enabled us to 
break the DMN into its various subregions, while still maintaining 
appropriate degrees of freedom. ICA is a data driven approach that 
allows for more adaptation to individual subject variability, which is 
essential in special populations, particularly those with atrophy as in 
our sample. The Default Mode and its subnetworks are relatively 
robust, and can easily be identified in a higher order ICA model148,180. 
We chose an ICA approach as it can be more sensitive to sample 
characteristics, such as brain atrophy in older populations, than 
standard atlas based seed-regions while still accurately identifying 
regions of interest181,182.  
To identify our regions of interest, we correlated all non-
artifactual components183 with templates of the default mode network 
and chose components with the highest correlation values to the 
templates (0.80 cutoff threshold).  Using the default mode network 
subdivisions and coordinates outlined by Andrews-Hanna,64 we 
identified 11 components that contained our regions of interest for 
the DMN subsystems. Components were manually confirmed using 
the xjview toolbox(http://www.alivelearn.net/xjview/) to ensure that 
Figure 2 Empirically derived 
component maps of nodes according to 
each DMN subsystem.  TP=  temporal pole, 
vlTC= ventro-lateral temporal cortex, 
dmPFC= dorsomedial prefrontal cortex, 
dlTC= dorso-lateral temporal cortex, TPJ= 
temporal parietal junction, 
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they contained only our regions of interest. Regions included the temporal pole (TP), lateral temporal 
cortex (2 regions; ventrolateral (vlTC) and dorsolateral (dlTC), dorsomedial prefrontal cortex(dmPFC), 
and the temporal parietal junction(TPJ) which comprised the dorsomedial subsystem. The 
parahippocampal gyrus (pHG), hippocampus, and posterior inferior parietal lobule (pIPL) comprised the 
medial temporal lobe subsystem. Finally, the precuneus, posterior cingulate (PCC), and ventromedial 
prefrontal cortex (vmPFC) comprised the midline core subsystem (Fig. 1). We then calculated functional 
connectivity in GIFT by correlating the time courses of signal fluctuations between the chosen 
components, and obtained a correlation value for each region pair for a total of 55 measures of pairwise 
connectivity.  
 
Statistical Analyses 
 Statistical analysis was performed in IBM SPSS 24.0 (Armonk, NY) and R version 3.3.3.184  
MANCOVA was used to determine if race modifies DMN connectivity according to cognition. First, we 
analyzed baseline connectivity differences (only within controls). Measures of intra-network connectivity 
between the DMN nodes were the dependent variables; cognitive scores, race, sex, age, and mean 
framewise displacement (MFWD) were independent variables. Next, we analyzed data from all 
participants using the same model, but included a higher order interaction term (race X cognitive scores). 
Separate models to additionally account for effects of APOE ε4, ABCA7 risk allele, hypertension, total 
white matter hyperintensity (WMH) volume, cardiovascular risk score, and diabetes on DMN 
connectivity were also analyzed.  For race-dependent connectivity changes, we accounted for multiple 
comparisons through the Benjamin-Hochberg method.185  False discovery rate was limited to 10% given 
our sample size and the number of nominally significant interactions with race.   
The same analysis was repeated according to Aβ42 levels in all subjects.  Because there is 
significant overlap in t-Tau levels between NC and AD, we performed a third analysis according to t-Tau 
levels only in subjects with reduced Aβ42 levels (<192 pg/mL)186consistent with cerebral amyloid 
deposition.187  Compared to using uncorrected nominal p<0.05 as a threshold, we reduced the number of 
23 
race-dependent node pairs from 23 to ten (six to four for cognition, from ten to two for CSF Aβ42, and 
from seven to four for CSF t-Tau).  Because we observed an over-representation of race’s effect on inter-
subsystem connectivity between nodes belonging to the midline core and dorsomedial (midline-
dorsomedial) subsystems regardless of the measure used for AD (cognition, Aβ42, t-Tau), we used 
bootstrapping (see below) to test whether the midline-dorsomedial connectivity was preferentially 
modified by race in AD compared to intra-subsystem and other inter-subsystem node pairs.  Finally, as 
confirmation, we used analysis of covariance (ANCOVA) to determine whether race influenced the mean 
midline-dorsomedial connectivity, midline-temporal connectivity, and dorsomedial-temporal connectivity 
adjusting for diagnosis, age, and gender.  Mean subsystem connectivity156 was calculated by averaging, 
for each individual, all pairwise inter-subsystem node pair connectivity between the two subsystems in 
question (15 pairs in midline-dorsomedial, 9 pairs in midline-temporal, and 15 pairs in dorsomedial-
temporal). 
Bootstrapping 
We developed a novel simulation-based approach to test whether there was empirical enrichment, 
or over-representation, for race modifying connectivity between midline core and dorsomedial 
subsystems.  To determine the likelihood of a concentration of significant interaction terms occurring by 
chance alone, we first obtained p-values for all Race x Cognitive Z-score interaction term for all potential 
node pairings (n=55; all subjects), and repeated the process for Aβ42 (n=55; all subjects) and t-Tau 
(n=55; only in subjects with Aβ42 < 192 pg/mL).  
 As these AD features are inter-related, we pooled all 165 (55 x 3) p-values together, and used 
bootstrapping analysis (“boot” package in R,188 with replacement) to create 1,500 simulated 3x5 (size of 
midline-dorsomedial matrix) matrices of p-values.  The number of “chance-only” matrices (out of 1,500) 
with three or more significant p-values is thus the probability of an observed concentration in any random 
3x5 matrix of node pairs resulting from chance alone.  At the same time, because this probability can be 
artificially reduced by a more stringent threshold at the matrix level (e.g., four or more significant p-
values), we created a second set of 1,500 simulated p-value matrices through the same bootstrapping 
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process to represent the range of possible midline-dorsomedial p-values.  Instead of drawing from all 
potential p-values, these 1,500 matrices were then only sampled from p-values pooled from the 45 
interaction p-values between midline-dorsomedial node pairs (n=15 each for Race x Cognitive Z-score, 
Race x Aβ42, and Race x t-Tau) (Figure 2).  The probability of having three or more significant p-value 
in each matrix in this second bootstrap is then compared with the first using Chi-squared test. We 
compared the proportion of significant vs. non-significant p values across the two bootstrapped 
distributions. The null hypothesis for this test was that the number of samples that contained more than 
three significant p values would not differ between the midline-dorsomedial bootstrap and the chance-
only bootstrap. We elected to use 1,500 as the bootstrap size as it is well within the commonly 
recommended threshold,189 but still a tiny fraction of all possible combinations.  
 
Figure 3  Illustrated workflow of the p-value bootstrapping analysis to confirm concentration of 
race’s effect on midline-dorsomedial connectivity.  Filled boxes represent node-pair connectivity 
modified by race, and empty boxes represent node-pair conne 
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2.3 Results 
Baseline connectivity differences 
We first compared baseline connectivity profiles between 
older African Americans and Caucasians with NC (n=58, Fig 3).  
Compared to Caucasians, African Americans had lower connectivity 
between the precuneus and the ventro-lateral temporal cortex (by 
0.31, 95 %         CI -0.16, -0.46, p=0.01), the inferior parietal lobule 
and parrahippocampal gyrus (by -0.15, 95 % -0.28, -0.03, p=0.01), and the 
temporal pole and hippocampus (by 0.19, 95 % CI -0.33, -0.04, 
p=0.01; Table 3).  There were otherwise no baseline connectivity 
differences in the remaining 52 inter-nodal connectivity values 
between the two racial groups. 
 
 
Race-independent changes centered in the medial 
temporal lobe subsystem of DMN  
 Because AD is characterized by reduced CSF Aβ42, 
increased CSF t-Tau, and cognitive impairment, we first analyzed the 
relationship between DMN connectivity, AD biomarkers (cognitive 
Z-score, Aβ42, t-Tau), and race to determine when race did not modify 
the relationship between AD biomarker and connectivity.  In both African 
Americans and Caucasians, lower (more abnormal) Aβ42 levels 
correlated with decreased connectivity between the inferior parietal lobule 
and the parrahippocampal gyrus (B= -.01, t(167)=-2.14, p =0.02).  
Because there is overlap in CSF t-Tau and p-Tau181 levels between 
Figure 4 Baseline connectivity 
differences between older African Americans 
and Caucasians with NC (p<0.04). Among nodes 
distributed along the three subsystems, three 
node pairs’ connectivity differed between the 
races.  In all instances, African Americans 
(green) with NC had lower connectivity between 
these node pairs than Caucasians (blue; bars 
represent mean values). TP=  temporal pole, 
vlTC= ventro-lateral temporal cortex, dmPFC= 
dorsomedial prefrontal cortex, dlTC= dorso-
lateral temporal cortex, TPJ= temporal parietal 
junction, pIPL= posterior inferior parietal lobule, 
pHG=parrahippocampal gyrus, vmPFC= ventro-
medial prefrontal cortex, PCC= posterior 
cingulate cortex. 
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controls and AD even though their levels are elevated at the group level, we restricted t-Tau-related 
analysis to those with Aβ42 levels consistent with AD (< 192 pg/mL).   
This also showed higher (more abnormal) t-Tau levels to correlate with decreased connectivity 
between multiple region pairs within the DMN, including hippocampus-temporal pole (B= .04, 
t(167)=1.58, p =.02) (Figure 4).  Connectivity correlated with cognitive impairment regardless of race 
appeared to occur between the medial temporal lobe and the midline core subsystems, and between the 
medial temporal lobe and the dorsomedial subsystems (Table 4, Figure 4). 
 
Figure 5 Race independent connectivity associations with biomarkers. Lines represent regions 
pairs for which connectivity was significantly related to the particular AD biomarker regardless of race 
(dashed line indicate CSF tau, solid line indicates cognition, and dotted line indicates CSF amyloid, red 
for positive relationship, blue for negative relationship, and grey for a relationship that did not survive 
correction for multiple comparisons). TP=  temporal pole, vlTC= ventro-lateral temporal cortex, dmPFC= 
dorsomedial prefrontal cortex, dlTC= dorso-lateral temporal cortex, TPJ= temporal parietal junction, 
pIPL= posterior inferior parietal lobule, pHG=parahippocampal gyrus, vmPFC= ventro-medial prefrontal 
cortex, PCC= posterior cingulate cortex. 
Race selectively modified the relationship between AD biomarkers and connectivity only 
between the MTL and Dorsomedial subsystem nodes 
We next examined node pairs whose connectivity relationship with AD biomarkers was modified 
by race (Table 5, Figure 5). In Caucasians, greater cognitive impairment was associated with decreased 
DMN connectivity between the precuneus and lateral temporal cortex, and between the precuneus and the 
temporal pole.  However, the opposite is true in African Americans, with greater cognitive impairment 
associated with increased connectivity between these same regions.  Similarly, lower (more abnormal) 
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Aβ42 levels correlated with greater connectivity between the precuneus and both lateral temporal cortex 
and dorsomedial prefrontal cortex only in African Americans.  Higher t-Tau levels (in those with Aβ42 
levels < 192 pg/mL) also correlated with greater connectivity between the lateral temporal cortex and 
precuneus, and between the temporal pole and both vmPFC and precuneus, and between the hippocampus 
and PCC, again only in African Americans.  Adjusting for risk genes (ABCA7, APOE) and other factors 
(hypertension, cardiovascular risk score, white matter hyperintensities, and diabetes) did not significantly 
influence connectivity values and race-associated differences persisted in connectivity relationship.  
 
Figure 6 Connectivity and biomarker relationships in African Americans for which interaction 
term regression coefficient (race X biomarker) is significantly greater than zero. Figure depicts regression 
relationship between connectivity and biomarkers in African Americans. Red line indicates connectivity 
increases as disease burden for that biomarker increases (see indication for each biomarker). Blue line 
indicates connectivity significantly decreases as disease burden for that biomarker increases (see 
indication for each biomarker). Gray outline indicates no significant relationship for African Americans 
28 
between connectivity and biomarker. Dashed line indicate CSF tau, solid line indicates cognitive 
performance, and dotted line indicates CSF amyloid. *=NHWs had significantly stronger (more negative) 
relationship than AAs. TP=  temporal pole, vlTC= ventro-lateral temporal cortex, dmPFC= dorsomedial 
prefrontal cortex, dlTC= dorso-lateral temporal cortex, TPJ= temporal parietal junction, pIPL= posterior 
inferior parietal lobule, pHG=parahippocampal gyrus, vmPFC= ventro-medial prefrontal cortex, PCC= 
posterior cingulate cortex.  
 
Visualizing race-independent (Fig 4) and race-dependent (Fig 5) DMN changes in AD, we 
observed a pattern of race-specific changes involving connectivity between two subsystems.  Whereas 
race-independent connectivity occurred between each pair of subsystems, nine out of ten race-dependent 
connectivity changes were between the midline core and dorsomedial subsystems.  For each subject, we 
calculated a mean connectivity value by averaging the all node-pair connectivity values between two 
subsystems.   
We further tested whether the midline-dorsomedial connectivity had an over-representation of 
node pairs whose connectivity was modified by race compared to the rest of DMN, we used bootstrapping 
(with replacement) to create 1,500 simulated 3x5 matrices drawn from midline-dorsomedial node pairs 
and 1,500 simulated matrices drawn from all node pairs.  We found that drawing from the midline-
dorsomedial matrices was more likely to result in identifying at least three significant race X AD 
biomarker effect than drawing from all node pairs: 791/1500 in the midline-dorsomedial sample vs. 
192/1500 in the chance-only sample, X2 (2, N=3000)=487.53, p= 0.00001.  ANCOVA adjusting for 
diagnosis, age, and gender confirms a main effect for race (F(2, 119)=3.255, p=0.074) for mean midline-
dorsomedial connectivity, but not for mean midline-temporal connectivity (F(2,119)=0.061, p=0.8060) or 
mean dorsomedial-temporal connectivity (F(2,119)=1.418, p=0.236).     
2.4 Discussion 
 Consistent with previous work, we found AD to alter connectivity between the medial temporal 
lobe and dorsomedial subsystems, but we identify race-specific changes associated with these alterations 
190,191. Importantly, we extend the effect of race on AD-related connectivity from the inter-nodal level to 
the inter-subsystem level through a novel analytical strategy.  To the best of our knowledge, this is the 
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first attempt to statistically identify enrichment of a factor’s effect on connectivity between two 
subsystems across multiple related measures (cognition, Aβ42, t-Tau).  The implication of this inter-
subsystem effect is not well understood.  Other conditions previously observed to confer similar 
specificity on inter-subsystem connectivity include PTSD,192 depression,193 and schizophrenia.194 
Interestingly, some of these conditions show racial disparities (schizophrenia195 and PTSD196 are more 
common in African Americans than Caucasians).  The inter-subsystem specificity may reflect shared 
vulnerability to neuropsychiatric disorders in African Americans, existence of disease subtypes, or 
divergent disease-associated pathways. We discuss these possibilities in the context of AD in African 
Americans below.  
In contrast to a uniformly slow disease process in African Americans, it is also possible that the 
multiple pathologic processes in AD may not proceed at the same pace in African Americans.  In post-
mortem studies of AD (involving primarily Caucasians), Aβ42-rich neuritic plaques are found early in the 
medial temporal as well as neocortical regions154. In contrast, tau-related changes appear in the medial 
temporal lobe before a stage-wise involvement of the frontal and then parietal cortical regions154. If we 
can interpret these observations as early co-localization of neuritic plaques and neurofibrillary tangles in 
the medial temporal lobe, the race-independent effect on inter-subsystem connectivity involving this 
region is in keeping with shared early AD changes by older African Americans and Caucasians when CSF 
Aβ42 alterations are detectable.  The attenuation of midline-dorsomedial connectivity in African 
Americans could then be interpreted as early compensation when AD is mild, or as pathological hyper-
connectivity 197,198. This would support the diminished cognitive reserve hypothesis in African Americans 
(potentially due to vascular disease199), and the prevailing longitudinal models that African Americans 
have slower decline in the presence of AD pathology.12,200  At the same time, the correspondence between 
ante-mortem DMN connectivity changes and post-mortem lesional mapping is known to be imperfect.  
For example, we found connectivity involving the posterior inferior parietal lobule (pIPL, a node in the 
medial temporal lobe subsystem) to be affected by AD independent of race.  This may suggest pIPL to be 
a locus of early AD pathology, but neurofibrillary tangles do not appear in this region until later in AD.201  
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The identified disparities in cognition and its relationship to functional connectivity are in 
keeping with current understanding of the African American cognitive profile in AD. African Americans 
exhibited an inverse relationship between cognition and FC compared to Caucasians such that as 
cognitive impairment increased, connectivity also increased. Typically, in AD, connectivity decreases as 
cognitive impairment increases. However, an increase in connectivity can be a result of disease 
processes198. An increase in connectivity in the mild cognitive impairment stage of AD, and in the 
presence of vascular disease is a fairly common finding199. Africans Americans generally exhibit slower 
cognitive decline in AD, and this increased connectivity could reflect an extension of early disease 
processes that generate the increased connectivity seen in many MCI studies.  
Other than milder AD-related tau pathology, the selectivity of race for midline-dorsomedial 
connectivity could result from non-AD pathologies outside these two subsystems or neuro-protective 
changes along the tracts connecting two subsystems.  Limited autopsy studies have shown African 
Americans more likely than Caucasians to have mixed AD and vascular lesions,114 and we previously 
showed in this cohort that African Americans experienced greater cognitive impact than Caucasians from 
the same degree of WMH.15  In the current study, we did not find total WMH volume to be related to race 
and connectivity.  However, the impact of regionally specific WMH has yet to be examined. The baseline 
differences in connectivity suggest existing differences in brain function separate from disease 
mechanisms that could be related to vascular disease, but the nature of these differences is not well 
understood, and the inclusion of vascular disease in our regression models did not alter our results. 
Although hypertension was more prevalent in our African American cohort, and African Americans had 
elevated cardiovascular risk scores, when we included this variable in our analyses, it did not explain the 
variability associated with race. Our identification of race-associated changes in midline-dorsomedial 
connectivity would support a search for WMH changes outside of these two subsystems.  Alternatively, 
Caucasians may be more likely to have WMH between these two subsystems.202   The vascular load in 
our cohort was mild to moderate, as it is not feasible, or ecologically valid to recruit older patients with 
minimal vascular disease. There are a variety of risk factors and contributing comorbidities for 
31 
Alzheimer’s Disease. It is possible that the various risk factors associated with AD may be different 
across different ethnic groups, such that AAs may have an increased vascular component of AD, while 
exhibiting AD pathology sufficient to meet diagnostic thresholds. WMH and AD are not mutually 
exclusive, and many have stated that WMH are a core feature of AD203,116, and a better predictor of 
disease burden in African Americans204. Future research will explore region-specific WMH between races 
and whether these differences relate to observed connectivity biomarker relationships.  
It would be remissive to not explore social factors which may contribute to these biological 
disparities.  The current work is the first to establish AD-related connectivity difference between races, 
and extends the neurobiological phenotype of AD in African Americans beyond a higher prevalence.  
How historical and current social inequalities may interact with genetic and environmental risks to give 
rise to these biological endpoints remains unknown. A variety of social disparities including income 
(amount vs. purchasing power), education (length vs. quality), and discrimination may additively or 
synergistically converge on the same biological endpoints. When analyzed separately, these factors may 
individually correlate with racial disparity but fail to capture the entire range of exposures facing different 
groups.  For example, individuals who experience racial discrimination and perceive it as such are more 
likely to have higher blood pressure and increased psychological distress,205,206,207 which in turn are risk 
factors for AD.208  Chronic stress also increases connectivity between the DMN and other networks at 
least in young adults,209 and may in part account for baseline and AD-related connectivity differences 
between the two racial groups.  We did not include household income as a surrogate measure of lifelong 
socioeconomic status because the two measures poorly correlate in retired people, and the sample size 
limited our ability to interpret results when we introduced a measure such as the Area Deprivation 
Index210. A larger sample size will be necessary to test mediation effects between discrimination, stress, 
cardiovascular disease, and negative health outcomes, and cohort studies need to explore biologically 
meaningful methods to characterize individual and group-based experiences of injustice.  
While we present the first biomarker-informed analysis of DMN inter-subsystem connectivity in 
African Americans, there are a number of limitations to our study. We tested two common AD risk 
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genotypes as mediators for race-associated differences, but we did not perform extensive genomic 
association analysis because of sample size.  While we observed multiple race-associated differences in 
DMN connectivity using ICA, we did not perform seed-based analysis of other large-scale brain networks 
(e.g., salience network).  This cohort’s African American participants had similar years of education and 
socioeconomic status as their Caucasian counterparts, but other medical, psychiatric, or psychosocial 
differences could contribute to inter-subsystem connectivity differences.  We did not identify a modifying 
effect of race on mean connectivity strength between the MTL and dorsomedial subsystem. Lastly, both 
racial groups include heterogeneous genetic backgrounds and in some cases mixed genetic heritage, so 
our results should be interpreted at the cohort level rather than the individual level.  Nevertheless, we 
present additional evidence that AD is associated with systematic biomarker differences between older 
African Americans and Caucasians.  Because CSF t-Tau-related findings similar to ours were replicated 
in a separate US cohort,2 independent replication of these DMN findings will further highlight the 
importance of diversity, inclusion, and disparities in on-going effort to elucidate mechanism-related 
biomarkers in AD.  
2.5 Conclusions 
We previously identified that African Americans and Caucasians share the same AD-associated 
CSF alterations related to amyloid deposition, but different CSF t-Tau biomarker levels regardless of AD 
status.15 Here we extend our findings to show older African Americans and Caucasians have similar AD-
associated subsystem connectivity changes involving the medial temporal subsystems. However, we also 
demonstrate race-specific patterns of connectivity between the midline core and dorsomedial subsystems, 
that are in-line with current studies that suggest divergent tau relationships between races.  Race modified 
the relationships between AD biomarkers and connectivity between the medial temporal lobe and 
dorsomedial subsystems. We thus propose adding DMN connectivity to the list of biomarkers with race-
dependent alterations in AD.  Similar to CSF, rsfMRI profiles for AD established in pre-dominantly 
Caucasian cohorts may under-diagnose the disease when applied directly to African Americans, and 
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negatively impact the interpretation of clinical trial outcomes when rsfMRI is used as surrogate marker of 
AD. The current work further provides specific regions of interest for imaging-based and molecular 
investigation of disease mechanisms. 
 
  
34 
2.6 Chapter 2 Tables 
 
Table 1 Demographic information. Sample reported here is the final imaging cohort of all individuals who 
passed imaging quality control. Note: T-tests were performed to compare races in the whole cohort and 
within each diagnostic category. *p<.05, **p<.001.  MMSE and CogZ scores were significantly different 
between diagnostic categories such, NC having highest MMSE scores and AD having lowest(MMSE: NC 
vs MCI, p= .007, MCI vs AD, p<.0001, CogZ: NC vs MCI, p<.0001, MCI vs AD, p<.0001). 
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Overall 
(N=137) 
Normal 
cognition MCI AD 
 
Caucasi
an  
(n=72) 
African 
Americ
an 
(n=65) 
Caucasi
an  
(n=31) 
African 
Americ
an 
(n=27)  
Caucasi
an  
(n=25) 
African 
America
n 
(n=28) 
Caucasi
an  
(n=16) 
African 
America
n 
(n=10) 
Age, 
years 
(SD)  
70.90(7
.84) 
69.20(7
.49) 71.65(8.
39)* 
67.48(6.
17)* 
71.52(5.
82) 
70.07(7.7
4) 
68.50(9.
41) 
71.4(9.6
5) 
Gender 35(37) 43(29) 19(12) 17(10) 15(10) 12(16) 9(7) 6(4) 
Years of 
Education 
(SD) 
16.32(2
.85) 
16.15(2
.85) 16.81(2.
69) 
15.78(2.
66) 
17.08(2.
58) 
16.29(2.8
1) 
14.19(1.
94) 
16.80(3.
55) 
MMSE 
(SD) 
26.32(4
.90) 
26.91(3
.57) 
28.84(0.
86) 
28.00(1.
86) 
27.64(1.
68) 
26.67(2.3
4) 
21.37(3.
38) 
20.22(6.
18) 
Cognitive 
Z Scores 
(SD) 
-
0.78(1.
12) 
-
0.72(0.
99) 
0.07(0.5
1) 
-
0.11(0.5
1) 
-
0.88(0.8
6) 
-
0.67(0.59
) 
-
2.24(0.6
6) 
-
2.36(1.0
2) 
White 
Matter 
Hyperinte
nsity 
volume 
(mm3) 
3984.40 
(4110.1
0)  
3886.03
(4964.9
3) 
3306.81
(3337.3
2) 
2440.93
(2576.1
5) 
4018.66(
4080.03) 
4313.70(
5330.60) 
5243.68(
5333.14) 
6730.21(
7607.48) 
Having A
BCA7 risk 
allele,   (
%) 
 
 
23.67* 
 
 
43.10* 
29.00 44.40 24.00 50.00 12.50 30.00 
Have 
Diabetes, 
(%) 
 
5.67** 
 
33.80** 
6.50** 33.33** 0* 28.60* 12.50* 50.00* 
Have 
Hypertens
ion(%) 
 
 
45.83** 
 
 
72.31** 45.16 62.96 56.00 78.57 31.25* 80.00* 
CSF 
Aβ42, 
pg/ml 
(SD) 
148.35(
95.02) 
168.48(
128.86) 
199.93 
(132.30) 
165.27 
(89.8) 
199.11 
(141.02) 
134.69 
(90.99) 
77.65(47
.39) 
133.55 
(140.71) 
CSF t-
Tau, 
pg/ml 
(SD) 
72.84(4
9.63)** 
40.92(2
0.79)** 
51.68 
(30.96)*
* 
36.04 
(11.63)
** 
63.99 
(33.71)* 
35.44 
(13.67)* 
108.48 
(77.43) 
75.8 
(33.52) 
CSF p-
Tau, 
pg/ml 
(SD) 
17.58 
(8.97)*
* 
25.81 
(12.47)
** 
23.47(9.
71)** 
14.05 
(5.07)*
* 
25.01 
(13.42)* 
17.74(7.2
1)* 
33.53(14
.64) 
24.54(10
.27) 
CSF t-
Tau/Aβ42 
0.73 
(0.91)* 
0.24 
(0.22)* 
0.46(0.7
4)* 
0.15 
(0.12)* 
0.44(0.4
2)* 
0.22(0.14
)* 
1.36(1.1
6) 
0.55(0.4
1) 
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Table 2 Demographic information for individuals excluded from analysis who did not pass QC 
 
 
 
 
 
  
 
  
Table 3 
 Overall (N=8) 
Normal 
cognition MCI 
 
Caucas
ian 
(n=5) 
African 
American (n=3) 
Caucasi
an 
(n=4) 
African 
Americ
an 
(n=2)  
Caucasi
an  
(n=1) 
African 
Americ
an 
(n=1) 
Age, years 
(SD) 
69.78(
5.83) 65.20(10.25) 
71.65(8.
39) 
67.48(
6.17) 71.52 70.07 
Years of Education 
(SD) 
16.82(
2.85) 
 
16.25 (2.63) 
16.8(2.6
9) 
16.78(
2.66) 17.08  16.29  
MMSE (SD) 
27.82(
4.90) 28.91(3.57) 
28.9(0.8
6) 
27.75(
1.86) 27.64  26.67  
Cognitive Z Scores 
0.89(2.
62) 0.82(1.89) 
-
0.02(0.6
2) 
0.01(0.
71) 
0.84 
 
0.75 
 
Having ABCA7 risk 
allele,   
(number) 
 
1 
 
 
2 0 1 1 1 
Have Diabetes, 
(number) 0 
 
1 0 1 0.0 0 
Have Hypertension 
(number) 
 
2 
 
 
2 1 1 1 1 
CSF Aβ42, pg/ml 
(SD) 
133.34
(95.02) 139.81(140.36) 
200.93(
132.40) 
164.27
(98.6) 201.11  134.69  
CSF t-Tau, pg/ml 
(SD) 
72.84(
49.63) 40.92(20.79) 
51.68(3
0.96) 
36.04(
11.63) 63.99  35.438  
CSF p-Tau, pg/ml 
(SD) 
42.71 
(20.98) 29.90 (15.60) 
37.44 
(16.29) 
22.95 
(8.46) 29.65 17.25 
CSF t-Tau/Aβ42 
0.79(0.
81) 0.26(0.21) 
0.85(0.8
7) 
0.15 
(0.16) 0.46 0.22 
37 
Connectivity B (95% Confidence interval) 
Unadjusted 
p 
Storey’s 
q 
Temporal Pole to Hippocampus -0.19(-0.33, -0.04) 0.01 0.137 
Ventro-Lateral Temporal Cortex 
to Precuneus 
-0.31(-0.46, -0.16) 0.01 
<0.001 
Inferior Parietal Lobule to 
Parrahippocampal gyrus 
-0.15(-0.28, -0.03) 0.01 
0.495 
Table 3 Baseline differences in functional connectivity between African Americans with NC and 
Caucasians with NC, adjusting for age, gender, and APOE ε4 allele. 
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Table 4 Factors associated with AD biomarkers (unadjusted p ≤ 0.01) independent of race, 
adjusting for age, gender, mean framewise displacement, and APOE ε4 allele.  Unadjusted p-values which 
remain significant after Benjamini-Hochberg step-up correction for multiple comparisons are bolded.  
Storey’s q-values are also shown with FDR < 10%. MTL= Medial Temporal Lobe. IPL= inferior parietal 
lobule. 
 
Subsystems Connectivity  Factor 
B (95% Confidence 
Interval) 
Unadjusted p 
Storey’s 
q 
MTL to  
MTL 
Posterior IPL 
to 
Hippocampus 
Race 0.019(-0.29, -0.05) 0.387  
t-Tau 
0.002( 0.00, 0.003) <0.001 
<0.001 
Posterior IPL 
to Parra-
Hippocampal 
gyrus 
Race 0.32(-0.14, .25) 0.710  
Aβ42 0.02(0.008, 0.40) 0.010 1.000 
MTL to 
midline core 
 
 
Posterior IPL 
to Ventro-
medial 
prefrontal 
cortex 
Race -0.05(-0.30, 0.20) 
 
0.675  
t-Tau 0.002( 0.00, 0.003) 0.001 0.004 
Parra-
Hippocampal  
gyrus to 
Precuneus 
Race -0.10( -0.30, 0.23) 0.358  
t-Tau 0.002(0.00, 0.002) 0.008 0.147 
MTL to 
dorsomedial  
Temporal 
Pole to 
Hippocampus 
Race -0.10(-0.30, 0.10) 0.337  
t-Tau 0.002( 0.00, 0.003) 0.009 0.247 
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Subsystem Connectivity 
Pair 
Variable 
Name 
B(95 % 
Confidence Interval) 
Unadjusted p Storey’s 
q 
Dorsomedial 
to midline 
core 
Dorsomedial 
prefrontal 
cortex to 
precuneus 
Race -0.02( -0.30, 0.25) 0.861  
Cognitive 
impairment 0.04( -0.13, 0.04) 0.292  
Race * 
Cognitive 
impairment -0.14( 0.07, 0.25) 0.005 0.092 
Ventrolateral 
temporal 
cortex to 
precuneus 
Race -0.24( -0.59, 0.11) 0.170  
Cognitive 
impairment -0.08( -0.02, 0.19) 0.103  
Race * 
Cognitive 
impairment 0.18( 0.02, 0.17) 0.001 
 
0.055 
Race -0.05(-0.32, 0.21) 0.695  
t-Tau -0.003( -0.02, -0.002) 0.712  
Race * t-Tau 0.02( -0.03, -0.0002) 0.001 0.055 
Dorsomedial 
prefrontal to  
posterior  
cingulate 
cortex 
Race 0.29( 0.08, 0.50) 0.007  
Cognitive 
Impairment 0.05( -0.15, 0.03) 0.407  
Race * 
Cognitive 
impairment 0.18( 0.02, 0.17) 0.007 0.096  
Temporal 
Pole  
to precuneus 
Race 0.05( -0.18, -0.29) 0.667  
Aβ42 0.0003( 0.00, 0.01) 0.345  
Race * Aβ42 
-0.001( -0.002, -
0.00001) 0.004 
 
0.073 
Race -0.80(-0.29, 0.13) 0.442  
t-Tau -0.002( -0.01, -0.001) 0.736  
Race *t-Tau 0.003( 0.001, 0.006) 0.005 0.069 
Dorso-lateral 
temporal 
cortex  
to precuneus 
Race -0.21(-0.12, 0.36) 0.112  
Aβ42 0.0002( -0.0001, 0.01) 0.345  
Race * Aβ42 
-0.002( -0.003, -
0.00001) 0.002 0.055 
Race -0.21(-0.43, 0.02) 0.070  
t-Tau -0.001( -0.002, -0.02) 0.066  
Race * t-Tau 0.004( 0.001, 0.006) 0.003 0.083 
Race -0.074(-0.20,0.54)  0.004  
Cognitive 
impairment 0.27(-0.04,0.09) 0.001  
Race * 
Cognitive 
impairment 0.20( 0.05, 0.25) 0.002 0.055 
MTL to 
midline core 
Race -0.001( -0.22, 0.22) 0.900  
t-Tau -0.001( -0.03, 0.002) 0.199  
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Table 5. Factors differentially associated with AD biomarkers according to race (unadjusted 
p≤0.01), adjusting for adjusting for age, gender, mean framewise displacement, and APOE ε4 allele.  
Unadjusted p-values which remain significant after Benjamini-Hochberg step-up correction for multiple 
comparisons are bolded.  Storey’s q-values are also shown with FDR < 10%. MTL= Medial Temporal 
Lobe. IPL= inferior parietal lobule. 
  
Posterior 
cingulate to 
hippocampus Race * t-Tau 0.003( 0.001, 0.052) 0.004 0.073 
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3 Aim 1B: WHITE MATTER HYPERINTESITIES DO NOT ACCOUNT FOR 
CONNECTIVITY DIFFRENCES ACCORDING TO RACE. 
3.1 Introduction 
Previous research has identified race associated differences between brain connectivity and 
Alzheimer’s disease burden209. As defined by Andrews-Hanna, the default mode network is composed of 
3 functionally distinct subsystems (dorsomedial, midline core, and medial temporal subsystem)190. 
Connectivity between the default mode network typically declines as Alzheimer’s disease progresses59. 
However, this finding has primarily been replicated in Non-Hispanic Whites (NHWs) with middle to high 
socio-economic status20. In a previous study, we investigated Alzheimer’s disease biomarkers in the form 
of CSF tau, Aβ42, and cognitive performance and their relationship to default mode subsystem 
connectivity in a sample including both African Americans and NHWs. Within NHWs, as AD disease 
burden increased, connectivity between the dorsomedial and midline core subsystems typically decreased. 
However, within African Americans, as disease burden increased, connectivity between these same 
subsystems increased, even after for controlling for APOE e4 phenotype, and total WMH volume. A 
potential explanation for this discrepancy was that African Americans had differences in the regional 
distribution of white matter hyperintensities, as AAs had higher percentages of vascular disease and type 
2 diabetes210. As the regional white matter hyperintensity volumes became available, we analyzed the 
plausibility of this explanation. In this study, we examined regional white matter hyperintensities in DMN 
subsystems, as well as other subcortical structures to determine whether WMH explained the increase in 
connectivity relate to AD observed in African Americans.  
3.2 Methods 
Participants 
We used previously calculated functional connectivity values of a cohort that was ethnically 
similar to our previously studied cohort, with the exception that this cohort did not contain any AAs with 
Alzheimer’s disease (only NC and MCI). Briefly, each participant underwent a detailed interview for 
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demographic information, self-reported race (Caucasians of Hispanic or Latino ethnicity were not 
included in this study), vascular risk factors (coronary artery disease, congestive heart failure, atrial 
fibrillation, hypertension, hyperlipidemia, diabetes, suspected transient ischemic attack), other medical 
comorbidities (e.g., cancer), and medications (e.g., use of angiotensin-converting enzyme inhibitors or 
angiotensin II receptor blockers). Each participant was then assigned a diagnosis according to consensus 
criteria including those for NC, MCI, and AD dementia (global Clinical Dementia Rating of 1 or 2.) 
Cognitively impaired subjects suspected of having a non-AD dementia (vascular, Lewy body, and 
frontotemporal dementia) were excluded.  Information for this cohort is available in the “cohort 1” 
information in chapter 4, table 1.  
MRI data collection & Analysis 
Scanning protocol included a T1-weighted 3D MPRAGE sequence (TR/TI/TE = 
2400/1060/2.31msec, flip angle = 8o, matrix =320x300, and voxel size = 0.8×0.8×0.8mm3) and a 6 minute 
eyes-open resting state functional MRI scan (TR/TE = 724ms/32ms flip angle = 52o, field of view 
(FOV) = 220 × 220 mm2, acquisition matrix = 104 × 104, voxel size = 2 × 2 × 2 mm3, slice = 91, time 
point = 550), and a T2-weighted Fluid attenuated inversion recovery (FLAIR) scan (TR/TI/TE = 
9000/2500/91 msec, flip angle = 150o, matrix =256x256, and voxel size = 0.8×0.8x5mm3).  
We conducted preprocessing pipelines with identical procedures for each cohort. To control for 
the difference in scanning parameters, we included cohort as a fixed effect in our statistical models. We 
utilized a standard preprocessing pipeline utilizing the DPARSFA toolbox 170. The first 10 timepoints 
were removed, scans were slice time corrected, manually re-oriented, realigned, normalized and smoothed 
using the DARTEL & algorithm211. This algorithm is more appropriate than standard normalization to the 
MNI template for special populations, such as those with atrophy. We then performed nuisance covariate 
regression (Friston’s 24 parameter head motion regressors, CSF, WM). We further removed motion-
confounds using ICA-AROMA and applied a high pass filter.  
Regional WMH analysis 
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Regional WMH volumes were derived from T2-weighted fluid-attenuated inversion recovery 
images software developed by researchers in the Brickman Lab at Columbia University 212. Briefly, each 
participant's fluid-attenuated inversion recovery image was corrected for intensity normalization, then 
skull-stripped and intensity normalized again. The skull-stripped images were sent through a high pass 
filter at the mode of the distribution of the image voxel intensity values. A half Gaussian mixture model 
was fit to the log-transformed histogram of the intensity values of each image. The Gaussian distribution 
that encapsulated the highest intensity values defined the hyperintense voxels and was labeled. Any 
cluster of labeled voxels that comprised fewer than five voxels was removed from the mask. The labeled 
images were visually inspected and false positives removed. The number of labeled voxels was summed 
and multiplied by voxel dimensions to yield a total volume in cm3. We obtained FLAIR data from 
individuals in Cohort 1 (Table 7) and performed this analysis on these 66 individuals. 
Seed based analysis  
We performed a seed based analysis using the regions described by Andrews hanna, et al.62 in the 
3 DMN subnetworks, namely: the Dorsomedial subsystem (DM): temporal pole, temporal parietal 
junction, lateral temporal cortex, dorsomedial prefrontal cortex; Medial temporal lobe subsystem (MTL): 
Hippocampal formation, parahippocampal cortex, retrosplenial cortex, posterior inferior parietal lobule, 
ventromedial prefrontal cortex; Midline core (MC): anterior medial prefrontal cortex, posterior cingulate 
and precuneus. We calculated measures of pairwise connectivity between each pair of regions, for a total 
of 56 measures of pairwise connectivity.  
DMN WMH value 
To obtain measures of DMN WMH across the subnetworks, we added together volumes across 
the subnetworks to obtain a volume of WMH for each subnetwork. For the MTL we included bilateral 
Hippocampal formation, parrahippocampal cortex, retrosplenial cortex, posterior inferior parietal lobule. 
For the MC we included the anterior medial prefrontal cortex and posterior cingulate and precuneus. For 
the DM subsystem we included temporal pole, temporal parietal junction, lateral temporal cortex, 
dorsomedial prefrontal cortex.  
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Statistical analysis 
DMN WMH across races 
To determine whether there was a difference between racial groups in DMN WMH volume, we 
constructed one multivariate linear model with the DMN WMH volumes as the outcome variable. Racial 
group was modeled as a fixed factor, and our covariates were age, gender, and APOE e4 status.  
DMN WMH and connectivity 
Because we previously identified racial differences in the relationships between connectivity and 
AD biomarkers for connectivity between the midline core and dorsomedial subsystems, we focused on 
these connectivity measures for the WMH analysis. We constructed linear regression models with our 
connectivity measures between the nodes of the midline core and dorsomedial subsystems as our outcome 
variables, and race and WMH volume as our independent variables of interest, while controlling for age, 
gender, and APOE status.  Additionally, we constructed a race by diagnosis interaction term to determine 
whether the relationship between WMH and connectivity differed according to racial group.  
To determine whether WMH within DMN nodes accounted for the racial differences that we 
identified in our previous work, we constructed Race X AD biomarker interaction terms (CSF Aβ42, CSF 
tau, and MoCA scores). We used these biomarker interaction as dependent variables, with the 
aforementioned covariates. We then included the three default mode WMH scores as independent 
variables to determine whether WMH accounted for racial differences we observed.  
3.3 Results 
DMN WMH across races 
There was no significant difference between racial groups in WMH volume of the DMN 
subnetworks: DM(B=0.02, t(3,72)=1.24, p=0.22), MTL(B=0.004, t(3,72)=0.16, p=0.88), MC(b=0.02, 
t(3,73)=0.42, p=0.68). The only subnetwork that had a large proportion of individuals that did not have 
any WMH was the DM subnetwork. Chi-squared tests for distribution of WMH across races for this 
subnetwork were not significant.  
45 
DMN WMH and connectivity 
In this re-analysis of the data, we were able to replicate one of our previous findings. There was a 
significant race x CSF Aβ42 interaction term for connectivity between the dorsomedial prefrontal cortex 
and the precuneus/posterior cingulate such that as CSF Aβ42 decreased, connectivity increased between 
these regions within AAs(B=-0.002, t(5,26)=-2.02, p=0.05).  We were not able to replicate our previous 
findings according to CSF t-Tau and cognition (Table 6).  
WMH volume within the specific regions of interest as well as within the midline core and 
dorsomedial subsystems was not related to our interaction terms. Because we had such a small number of 
regions for which the race X biomarker term was significantly relate to connectivity, we also included the 
dorsomedial prefrontal cortex and precuneus WMH volumes in our analysis. The inclusion of subsystem 
total WMH volumes within the MC, DM, and regional dorsomedial prefrontal cortex and precuneus 
WMH volumes into our model did not reduce the significance of the interaction term for the Aβ42 X 
Race interaction term.  
3.4 Discussion 
DMN white matter hyperintensity volumes were not significantly different between races, nor 
were there distributional differences between races. This indicates that the underlying cause of the 
disparate connectivity to biomarker relationships that we previously observed may not be the presence of 
WMH within these nodes. These findings lend credence to the hypothesis that WMH and Abeta have 
separate etiologies, but these findings should be considered with caution for the reason mentioned below. 
While we cannot say definitively that DMN WMH do not account for the observed differences in race to 
biomarker relationships, this preliminary data does suggest that the WMH in the DMN do not have a 
robust effect on connectivity.  Other hypotheses about the nature of the disparities are that African 
American connectivity profiles may be different as a result of tau distribution, as African Americans have 
lower tau.  
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While understanding the mechanism behind functional connectivity disparities has significance 
for treatment interventions and disease etiology and progression, the lack of a clear mechanism in this 
body of work does not make it insignificant. It is important to rule out potential biological mechanisms 
that could explain health disparities before jumping to social explanations as the cause. In this case, 
WMH did not explain the disparate Aβ42 to connectivity relationships we observed in this cohort, and 
thus it will be appropriate to explore other biological mechanisms and social constructs, (i.e. cytokines144 
or perceived stress124) that exhibit disparities along racial lines.   
It is difficult to transpose the findings from this analysis onto our previous results. This analysis 
was conducted in a separate, smaller cohort. We detected less significant race X biomarker interaction 
terms than our previous analyses. This is likely because this analysis is underpowered, and we did not 
have any AA individuals with AD in this cohort, which makes this particular sample non-representative 
of the AA with dementia population at-large. The lack of significant findings in this cohort should not be 
taken as evidence that WMH do not play a role in DMN connectivity, rather that our sample size was 
likely insufficient to detect a significant result, as previous studies with larger sample sizes have identified 
relationships between WMH and DMN connectivity in the context of AD4,213,214. An alternative 
explanation could be that WMH within the regions that we analyzed may not influence connectivity, and 
that other regions outside the DMN subnetworks may be influencing connectivity.  
We conducted power analysis to determine how many people we would need to detect a 
significant effect given the effect size of our interaction terms. Using the “pwr” package in R. we 
determined that we would need a sample size of 118 to detect a significant effect, and our sample size of 
66 falls short of this number. We are currently obtaining images from a larger set of both AA and NHW 
individuals with NC that also have FLAIR and fMRI data, and we plan to mine the large OASIS dataset 
that includes both cross sectional and longitudinal FLAIR and fMRI data of over 700 individuals, with 
more than 100 who self-identify as African American215.   
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3.5 Chapter 3 tables 
Table 4 Results from the replication analyses in the cohort for which we obtained regional WMH 
volume. N= 66. dmPFC = dorsomedial prefrontal cortex, PCC = precuneus and posterior cingulate, TC = 
lateral temporal cortex, TempP = temporal pole.    
B t p 
dmPFC 
to PCC 
Race X 
CSF Aβ42 
-0.002 -2.02 0.05 
Race X 
CSF tau 
0.004 0.88 0.39 
Race X 
Cognition 
-0.03 -1.29 0.2 
LTC to 
PCC 
Race X 
CSF Aβ42 
-0.0001 -0.2 0.84 
Race X 
CSF tau 
-0.003 -0.74 0.5 
Race X 
Cognition 
-0.02 -1.5 0.15 
TemP to 
PCC 
Race X 
CSF Aβ42 
-0.001 -0.5 0.62 
Race X 
CSF tau 
0.001 0.3 0.77 
Race X 
Cognition 
-0.02 -1.6 0.11 
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The following manuscript was submitted for publication and is under review at Brain Connectivity. We 
have reprinted it here for the purposes of satisfying the dissertation requirements.  
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Abstract 
Background: Pathologic and functional studies of Alzheimer’s disease (AD) indicate fronto-
putaminal networks as sources of neurological changes in response to disease. However, limited research 
has examined AD-associated changes in connectivity between the putamen and its supra- and infra-
tentorial outputs, and of their relationships with measures of ischemic injury. In this study, we set out to 
determine how functional connectivity between the anterior putamen (APu) and other brain regions 
relates to AD and regional white matter hyperintensity (WMH) volume. Because we previously identified 
disparate default mode network connectivity patterns between Black/African American (AA) and non-
Hispanic white (NHW) individuals according to AD, we also analyzed the impact of race on putamen-
related connectivity.  
Methods: In our sample of 267 individuals with normal cognition, mild cognitive impairment, 
and AD dementia, we measured functional connectivity between APu and multiple cortical regions. We 
then modeled the relationships between AD-associated features (cognition, CSF AD biomarker levels), 
regional WMH, APu-connectivity, and race.   
Results: Measures of AD (diagnosis, worse cognition, and decreased CSF Aβ42) were associated 
with increased connectivity between the APu and pre-/post- central gyrus in both races.  At the same time, 
race modified the relationship between connectivity and measures of AD between the APu and 
superior/middle frontal gyri.  Frontal and putaminal WMH also had more negative impact on the 
connectivity between APu and superior/middle frontal gyri in AA, even though WMH in the same 
regions had the opposite effects in NHW.  
Discussion: In this manuscript we argue three points: 1) AD alters connectivity between APu and 
its input (pre/post central gyrus) independent of race, 2) these changes extend to the superior and middle 
frontal gyrus in AAs, and 3) biomarkers of AD and WMH each exerted race-dependent influence on APu 
connectivity with the superior/middle frontal gyrus.  
Impact statement: This is the first study to specifically probe the APu-related connectivity 
according to AD and regional WMH volume. Similar to our prior observations in the default mode 
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network, APu connectivity to other brain regions is sensitive to race in some paths, yet independent of 
race in others.  These extend our previous finding that AD and vascular biomarkers are associated with 
differential – and sometimes opposite – functional consequences in AA and NHW. 
Acronyms: APu= anterior putamen, NC= normal cognition, AD= Alzheimer’s Disease, WMH= 
White matter hyperintensities, AA= African American, NHW= non-Hispanic white, DMN = Default 
mode network 
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4.1 Introduction 
While often overlooked in studies of Alzheimer’s disease (AD) research – including histological 
studies, PET, and structural neuroimaging – has shown the putamen and frontal lobe to be vulnerable to 
AD pathology as well as ischemic damage. The striatum, which includes the caudate and putamen, may 
exhibit amyloid deposition and AD-related atrophy as much as 10 years before symptom onset in 
individuals at risk for AD154, 215,216. Similarly, neuritic plaques as well as neurofibrillary tangles begin to 
appear in the frontal lobe in early and intermediate stages of AD217,218. The appearance of these pathologic 
lesions in AD has further been linked to neuronal dysfunctions through FDG-PET studies219,171,220,221 and 
MRI volumetric analysis77with the putamen much more affected by AD than the functionally-related and 
spatially adjacent caudate.  Therefore, an improved understanding of the putamen’s role in aging and 
early AD can provide a novel region for biomarker development and a potential target for clinical 
intervention studies.  
Functional connectivity is a widely used method for understanding disease related neurological 
changes. Functional connectivity is defined as a measure of the synchronicity of blood-oxygen level 
dependent (BOLD) signal between brain regions, typically collected during a resting-state functional 
magnetic resonance imaging scan 222. Within AD, the most studied regions lie within the default mode 
network (DMN) 223. There exist scientific rationale and precedent for examining the impact of AD on 
DMN 224, yet other local and large-scale brain connections are often overlooked 223.  The functional 
networks of the putamen are well-defined in neuroscience due to their importance in movement regulation 
and disease. Within the frontal lobe, the putamen is most structurally connected to the superior and 
middle frontal gyri, and pre and post central gyri86,126,108,225. These areas are thought to work together to 
meet visual spatial and motor demands226,227. The anterior putamen (APu) is classically viewed as a an 
associative region while the posterior putamen supports motor function 87.  The APu is also more affected 
by AD than its posterior counterpart in structural MRI88–90 and better correlates with cognitive decline91. 
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Because putamen’s connectivity with other brain regions is also most consistent across individuals among 
basal ganglia structures86, the APu is a logical focus of our investigation in AD.   
Consistent with this, limited evidence exists to implicate frontal-APu connectivity in AD228–230, 
but the opposite has also been reported231.  One caveat may be the presence of striatal – more specifically, 
putaminal – white matter hyperintensity (WMH) which is commonly observed in older individuals 
including those with AD 232. WMH has been linked to strokes and cerebrovascular risk factors (e.g., 
diabetes), 93 but also neuro-inflammation 233.  While there is agreement that total brain WMH volume is a 
risk factor for AD but is not a specific marker for AD, 234, it remains controversial whether WMH has 
uniform etiology or impact on cognition across the brain.  Region-specific WMH quantification 
implicates vascular disease to associate with amyloid deposition for posterior portion of periventricular 
WMH changes 94.  However, recent evidence indicates that WMH could emerge independently of 
vascular disease and arise as a direct inflammatory response to neuritic plaques in AD103,235.  
 Relevant to our APu connectivity analysis, WMH can disrupt BOLD synchronicity between 
brain regions 236. Decoupling of functional and structural connectivity increases as WMH burden 
increases on a global 236 and tract-specific scale108. In AD, regions of the DMN show decreased 
connectivity if the WM tracts connecting them have a high WMH burden166. Furthermore, WMH load in 
one WM tract can affect functional connectivity between nodes along a separate tract, suggesting direct 
and indirect impact on functional connections118. Regional distribution differences in WMH may generate 
unique functional network and therefore cognitive profiles that cannot be parsed apart by using total 
WMH volume. WMH typically correlate with tests of speed and executive function, and not with tests of 
fluid or crystallized intelligence102,237. This suggests that their presence may disrupt intracerebral brain 
connectivity, as tests of executive function rely on a coordinated effort of multiple brain regions to 
perform tasks 238. Due to their vascular origin and role in brain connectivity, regional WMH differences 
may explain many of the functional connectivity changes observed in aging and dementia. 
Like other AD biomarker studies, brain network analysis should examine potential differences 
between racial groups to test generalizability.  Independent of whether self-reported race reflects genetic 
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similarity according to region of ancestry, identification with an ethno-cultural group, or structural racism, 
there are real and observable biological outcomes from racial disparities which need to be measured 200. 
This is particularly true for studies of AD as African Americans (AA) are approximately twice as likely to 
develop AD in their lifetime as non-Hispanic whites (NHW), and are more likely to have existing 
comorbidities such as vascular disease and type-2 diabetes121,239,240. In keeping with AD biomarker 
differences between races, our previous DMN analysis showed disparate relationships between functional 
connectivity and AD biomarkers according to race 211. Specifically, AA individuals exhibited increased 
connectivity between two tau-related DMN subsystems as disease burden increased.  CSF studies have 
also shown African American individuals exhibit a unique tau – but not amyloid or neurofilament light 
chain – biomarker profiles15,241.  Given the complexity between AD, WMH, and race, here we present a 
study of APu connectivity in AA and NHW participants using three diverse cohorts recruited from the 
Atlanta area.  
4.2 Methods 
Data collection for all studies, including re-analysis of existing data were approved by the Emory 
University and Georgia State University Institutional review board.   
Participants 
Our analyses consisted of three cohorts of previously collected data from three studies. Separate 
tables for each cohort are included in the supplemental materials. Cohorts 1 and 2 (N=66 and 113; PI: Hu) 
recruited individuals over the age of 65 including individuals with normal cognition (NC), mild cognitive 
impairment (MCI), and AD dementia.  Cohort 3 (N=88, PI Wharton) was designed as a study of 
cardiovascular risk factors for dementia among African American women with normal cognition. Each 
participant underwent a detailed interview for demographic information, self-reported race (Caucasians of 
Hispanic or Latino ethnicity were not included in this study), vascular risk factors (coronary artery 
disease, congestive heart failure, atrial fibrillation, hypertension, hyperlipidemia, diabetes, suspected 
transient ischemic attack), other medical comorbidities (e.g., cancer), and medications (e.g., use of 
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angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers). Each participant was then 
assigned a diagnosis according to consensus criteria including those for NC, MCI, and AD dementia 
(global Clinical Dementia Rating of 1 or 2.) Cognitively impaired subjects suspected of having a non-AD 
dementia (vascular, Lewy body, and frontotemporal dementia) were excluded.   
For Cohort 3, middle-aged African American and Caucasian subjects were recruited into a study 
of cognitively normal subjects with a family history of AD dementia. Demographic (age, sex, education), 
diagnostic (syndrome, global Clinical Dementia Rating [CDR], Mini-Mental State Examination [MMSE]) 
and APOE allelic information were collected. Table 1 includes the demographic information across 
cohorts, and table 2 includes demographic information stratified by cohort. Total number of individuals 
with NC=187, MCI=53, AD=27.  
MRI data collection 
All participants were scanned on a Siemens 3T MRI machine at the Emory Center for Systems 
Imaging with scanning protocols for each cohort included below.  
Cohort 1 
Scanning protocol included a T1-weighted 3D MPRAGE sequence (TR/TI/TE = 
2400/1060/2.31msec, flip angle = 8o, matrix =320x300, and voxel size = 0.8×0.8×0.8mm3) and a 6 minute 
eyes-open resting state functional MRI scan (TR/TE = 724ms/32ms flip angle = 52o, field of view 
(FOV) = 220 × 220 mm2, acquisition matrix = 104 × 104, voxel size = 2 × 2 × 2 mm3, slice = 91, time 
point = 550), and a T2-weighted Fluid attenuated inversion recovery (FLAIR) can (TR/TI/TE = 
9000/2500/91 msec, flip angle = 150o, matrix =256x256, and voxel size = 0.8×0.8x5mm3).s  
Cohort 2 
Scanning protocol included a T1-weighted 3D MPRAGE sequence (TR/TI/TE = 
1620/950/3msec, flip angle = 30o, matrix = 192×256×160, and voxel size = 0.98×0.98×1mm3) and a 6 
minute eyes-open resting state functional MRI scan (TR/TE = 3000ms/32ms flip angle = 90o, field of 
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view (FOV) = 200 × 200 mm2, acquisition matrix = 64 × 64, voxel size = 3.1 × 3.1 × 3.5 mm3, slice = 33, 
time point = 124).  
Cohort 3  
Scanning protocol included a T1-weighted 3D MPRAGE sequence (TR/TI/TE = 
2300/800/2.89msec flip angle = 8o, matrix =256 x256x176, and voxel size = 1×1×1mm3) and a 4.25 
minute eyes-open resting state functional MRI scan (TR/TE = 3000ms/32ms flip angle = 90o, field of 
view (FOV) = 200 × 200 mm2, acquisition matrix = 220 × 220 x 144, voxel size = 2 x 2 x 2 mm3, 
slice = 48, time point = 170).  
MRI Data preprocessing 
We conducted preprocessing pipelines with identical procedures for each cohort. To control for 
the difference in scanning parameters, we included cohort as a fixed effect in our statistical models. We 
utilized a standard preprocessing pipeline utilizing the DPARSFA toolbox 172. The first 10 timepoints 
were removed, scans were slice time corrected, manually re-oriented, realigned, normalized and smoothed 
using the DARTEL & algorithm 213. This algorithm is more appropriate than standard normalization to 
the MNI template for special populations, such as those with atrophy. We then performed nuisance 
covariate regression (Friston’s 24 parameter head motion regressors, CSF, WM). We further removed 
motion-confounds using ICA-AROMA 242 and applied a high pass filter.  
Neuropsychological testing 
Each cohort utilized a different cognitive battery or test. Data collection for cohort 1 utilized a 
cognitive battery as previously described 15. Briefly, this battery included memory tests (Consortium to 
Establish A Registry for Alzheimer’s Disease word list delayed recall, Brief Visual Memory Test–
Revised [BVMT-R] delayed recall), (2) executive function tests (Trail Making Test B, reverse digit span 
[RD], Symbol Digit Substitution Test, and letter-guided fluency), (3) language tests (Boston Naming Test 
[60 items], category fluency), and (4) visuospatial function tests (Judgment of Line Orientation[JOLO], 
Rey-Osterrieth complex figure test). With the exception of BVMT-R, JOLO, and RD, subtest Z-scores 
were calculated according to published normative data, adjusting for age, sex, education, and race. Z-
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scores for the four domains were averaged to generate composite cognitive Z-scores. Neuropsychological 
data collection for cohort 2 included administration of the Montreal Cognitive assessment (MoCA). Data 
collection for cohort 3 included administration of the mini-mental state exam (MMSE). To control for the 
variety of scales and neuropsychological assessments between cohorts, we z-scored the data from cohorts 
2 and 3 according to race, and controlled for cohort in our statistical analysis.   In out statistical analyses, 
cognitive scores were multiplied by negative one so that an increasing score indicates declining cognitive 
performance.  
CSF collection 
CSF (20 mL) was collected using protocols modified from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) using 24G Sprotte atraumatic needles and syringe between 8AM and 
noon without overnight fasting, and transferred into two 15 mL polypropylene tubes. For the Emory 
cohort 3, CSF was centrifuged at 2,000 rpm for cellular studies; the supernatant was removed, 
immediately aliquoted (500 μL), labelled, and frozen (−80 °C) until analysis. Because CSF-tau is 
typically lower in African Americans 243, and tau related changes typically emerge after amyloid 
deposition (low CSF Aβ42) 244, we z scored CSF t-tau according to race, and only analyzed CSF t-tau 
within individuals with an amyloid z-score of less than 1. We multiplied CSF Aβ42 by -1 so that 
increasing amyloid levels indicate increasing amyloid burden.  
Area deprivation index 
To control for socioeconomic status, we utilized the online neighborhood atlas developed at the 
University of Wisconsin, Madison (https://www.neighborhoodatlas.medicine.wisc.edu/). Using 
participant addresses, we obtained area deprivation index scores.  
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Seed Based Analysis 
Using the Wake Forest University Pickatlas v3.0.5, we created 
an anterior and posterior putamen mask by creating a 9mm sphere 
around the center of the APu, and center of the posterior putamen in 
MNI space using coordinates outlined by Oberhuber et al., 2013, for 
each hemisphere (Yin et al., 2009. Frontal regions highly connected to 
the putamen, as determined by human tractography studies, include the 
superior frontal gyrus, precentral gyrus, middle frontal gyrus, 
postcentral gyrus (Cacciola et al., 2017). Additionally, the putamen is a 
highly lateralized region with strong ipsilateral connections (Cacciola et 
al., 2017). As such, we only considered connectivity values between 
ipsilateral nodes.  
We calculated seed to seed functional connectivity using the 
DPARSF-A toolbox. Using our own anterior and posterior putamen 
seeds and masks of the aforementioned regions as defined by the 
Automated Anatomical labeling atlas, we calculated connectivity 
between the putamen and these regions ( Table 3).    
Figure 7 Cross sectional images 
of the empirically defined anterior 
and posterior putamen seeds. 
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Figure 8 Visual representation of the connectivity measures used in this analysis. Supplemental 
figures include a 3-D representation of the seed maps. 
 
Regional white matter hyperintensity volumes 
Total WMH volumes were derived from T2-weighted fluid-attenuated inversion recovery images 
software developed by researchers in the Brickman Lab at Columbia University 214. Briefly, each 
participant's fluid-attenuated inversion recovery image was corrected for intensity normalization, then 
skull-stripped and intensity normalized again. The skull-stripped images were sent through a high pass 
filter at the mode of the distribution of the image voxel intensity values. A half Gaussian mixture model 
was fit to the log-transformed histogram of the intensity values of each image. The Gaussian distribution 
that encapsulated the highest intensity values defined the hyperintense voxels and was labeled. Any 
cluster of labeled voxels that comprised fewer than five voxels was removed from the mask. The labeled 
images were visually inspected and false positives removed. The number of labeled voxels was summed 
and multiplied by voxel dimensions to yield a total volume in cm3. We obtained FLAIR data from 
individuals in Cohort 1 and performed this analysis on these 66 individuals. 
Regional WMH load 
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Because we had many people that did not have a WMH in either the putamen or frontal nodes, 
rather than analyze the continuous volumes, we created scores that reflected whether a WMH volume was 
present in a particular region. To create regional WMH load, we coded volumes as 0 for not present in 
either the putamen or nodes in the analysis (pre and post central gyrus 1 for present in either putamen or 
sensorimotor nodes, and 2 for present in both putamen and sensorimotor nodes. We created a similar 
score using the same procedure for frontal nodes including the middle and superior frontal gyrus.  
Statistical analysis  
Anterior putamen connectivity and Alzheimer’s Disease Burden 
Diagnostic categories 
We created two multivariate linear regression models (one for each hemisphere) that included the 
8 pairwise measures of connectivity as dependent variables, self-reported race, gender, cohort, presence 
of hypertension and type-2 diabetes, and APOE ε4 carrier status as fixed factors, and age, area deprivation 
index, and mean frame-wise displacement as covariates. Diagnostic category was included as a fixed 
factor. We corrected for multiple comparisons using the Holm FWER correction method.  
AD biomarkers 
Next, we analyzed whether AD related biomarkers corresponded with observed connectivity 
changes. To further determine which disease biomarkers may be related to connectivity, we constructed 
models that did not include diagnosis, and instead included CSF t-tau, CSF Aβ42, cognitive scores, and 
putamen-frontal WMH scores, with the same covariates. We corrected for multiple comparisons using the 
Holm FWER correction method. To maintain consistency in presentation of our results, cognitive scores 
and CSF Aβ42 were inversed such that in our analyses and results, an increasing cognitive score indicates 
worse cognitive performance (greater cognitive impairment), and increasing CSF Aβ42 indicates 
increasing amyloid burden (lower CSF Aβ42).   
Racial differences in frontal to anterior putamen connectivity 
Racial differences in normal cognition 
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To establish underlying racial differences, we constructed two multivariate linear regression 
models (one for each hemisphere) that included the 8 pairwise measures of connectivity as dependent 
variables, self-reported race, gender, cohort, APOE ε4 carrier status, and presence of hypertension and 
type-2 diabetes as fixed factors, and age, area deprivation index, and mean frame-wise displacement as 
covariates. We corrected for multiple comparisons using the Holm FWER correction method. To 
maintain consistency in presentation of our results, cognitive scores and CSF Aβ42 were inversed such 
that in our analyses and results, an increasing cognitive score indicates worse cognitive performance 
(greater cognitive impairment), and increasing CSF Aβ42 indicates increasing amyloid burden (lower 
CSF Aβ42).  
White matter hyperintensities and connectivity 
We next wanted to establish whether there were regional differences between NHWs and AAs in 
individuals with mild cognitive impairment within and between the nodes of our fronto-putamen network, 
basal ganglia, and the default mode network. We did this using two methods; 1) Performed a chi-squared 
test to determine whether the distribution of WMH fronto-putamen scores was different according to race 
2) created a multivariate linear regression model that controlled for age, gender, and APOE ε4 status, and 
hypertension to determine whether WMH volume was significantly different between races within 
individuals with normal cognition.  
We also wanted to determine whether CSF Aβ42 was related to putamen frontal WMH load. In 
this linear model, CSF Aβ42 was the outcome variable. We controlled for age, gender, race, APOE ε4, 
and hypertension.  
Racial Differences in AD burden to connectivity relationships 
We next analyzed whether race modified biomarkers to connectivity relationships by constructing 
two linear mixed models that included diagnosis, CSF t-tau, CSF Aβ42, cognitive z-scores, and putamen 
frontal WMH scores and the following interaction terms: race X diagnosis, race X CSF t-Tau, race X CSF 
Aβ42 burden, Race X Cognitive impairment, and race X fronto-putamen WMH load. We included the 8 
pairwise measures of connectivity as dependent variables, self-reported race, gender, cohort, APOE ε4 
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carrier status, and presence of hypertension and type-2 diabetes as fixed factors, with age, area 
deprivation index, and mean frame-wise displacement as covariates. We corrected for multiple 
comparisons using the Holm FWER correction method. To maintain consistency in presentation of our 
results, cognitive scores and CSF amyloid were inversed such that in our analyses and results, an 
increasing cognitive score indicates worse cognitive performance (greater cognitive impairment), and 
increasing CSF Aβ42 indicates increasing amyloid burden (lower CSF Aβ42).   
4.3 Results 
Regions of interest 
We initially included separate ipsilateral nodes between the APu and the posterior putamen, 
caudate, insula, precentral gyrus, postcentral gyrus, middle frontal gyrus, and superior frontal gyrus, as 
these regions are the most structurally connected to the putamen (Cacciola, et. al, 2017). In our initial 
analyses, cognition and diagnosis were not significantly related to connectivity between the APu and the 
posterior putamen, caudate, and insula, and exhibited no racial differences in individuals with NC. Thus, 
we report here our analyses for connectivity measures between Apu and the following regions; pre and 
post central gyri, and middle and superior frontal gyri for the remainder of the results.  
APu connectivity and AD features 
Diagnostic categories 
After controlling for age, sex, race, and APOE ε4, connectivity between the right APu and the 
right precentral gyrus was significantly different among diagnostic categories (precentral: β=0.13, 
t(7,255)=1.65, p=0.05; postcentral: β=0.14, t(2,255)=1.79, p=0.05). Individuals with AD had significantly 
greater connectivity than individuals with NC and MCI between the right APu and the right precentral. 
(Table 3)  
Cognitive impairment 
 Connectivity between the right APu and pre and post central gyrus correlated with cognitive 
impairment such that as amyloid burden increased, connectivity also increased (pre-central gyrus: β=0.04, 
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t(6,251)=1.70, p=0.04;  postcentral gyrus: β=0.05, t(6,251)=2.21, p=0.03) (Figure 3A). There was no such 
finding in the left hemisphere. (Table 3)   
CSF biomarkers 
 Connectivity between the left APu and cortical regions correlated with Aβ42 burden (precentral 
gyrus: β=0.05, t(6,174)= 1.76, p=0.04; postcentral gyrus: β=0.05, t(6,174)= 1.68, p=0.05) (Figure 3B). 
CSF t-Tau was not significantly related to any of our connectivity measures of interest. Model results are 
included in the appendix.  
Regional WMH load 
 WMH load within pre and post central gyri and putamen was related to connectivity between 
the right and left APu and the respective pre and post central gyri. In the right hemisphere, as WMH load 
increased, precentral (β=-0.16, t(6,55)=-2.02, p=0.04) and postcentral(β=-0.18, t(6.55)=-2.43, p=0.01) 
gyrus connectivity decreased, and in the left hemisphere, precentral (β=0.09, t(6,55)=2.04, p=0.04) gyrus 
connectivity increased (Figure 3D).  Neither Regional WMH load was significantly related to CSF Aβ42, 
and when CSF Aβ42 was included in the WMH models, beta coefficients for functional connectivity 
values did not significantly change. Model results are included in the appendix. 
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Figure 9 Race independent connectivity to biomarker relationships. A) Amyloid and functional 
connectivity in the left hemisphere between the Apu and the pre and post central gyri.. Line color 
indicates region. B) Amyloid burden and functional connectivity in the right hemisphere between the Apu 
and pre and post central gyri. Line color indicates region. C) Regional WMH load and functional 
connectivity in the left hemisphere in cohort 2. Line color indicates region. D) Regional WMH load and 
functional connectivity in cohort 1 in the right hemisphere. Line color indicates region. Grey background 
indicates a 95% CI. E) Summary figure of race independent relationships. AA = African American, NC = 
normal cognition, WMH= white matter hyperintensities.  
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Racial differences in putamen connectivity 
Racial differences in individuals with normal cognition 
Within controls, African Americans had significantly lower connectivity than NHWs between the 
left APu and the left superior frontal (β=0.11, t(5,177)=2.10, p=0.04), left precentral gyrus (β=0.14, 
t(5,177)=2.31, p=0.02), left middle frontal gyrus(β=0.14, t(5,177)=2.79, p=0.01). In the right hemisphere, 
African Americans had significantly lower connectivity than NHWs between the right APu and the right 
middle frontal (β=0.16, t(6,167)=2.60, p=0.01), and right superior frontal(β=0.15, t(6,167)=2.54, p=0.01). 
The presence of type-2 diabetes, and hypertension, and area deprivation index scores did not account for 
the effect of race on connectivity. Model results are included in table 3.  
Racial differences in amyloid beta and fronto-putamen connectivity  
Race significantly modified the relationship between Aβ42 and connectivity between the left APu 
and left middle frontal gyrus (β=-0.12, t(7, 172)=-2.25, p=0.02), and the between the right APu and right 
middle frontal gyrus (β=-0.20,  t(7,172)=-3.30, p=0.001) and the right superior frontal gyrus (β=-0.16,  
t(7,172)= -2.36, p=0.02) such that within African Americans, as amyloid burden increased, connectivity 
decreased (Figure 4A). Model results are included in the supplemental table. 
Racial differences in regional WMH load and functional connectivity 
Race significantly modified the relationship between WMH load in the putamen, superior frontal, 
and middle frontal gyri and connectivity between the left APu and superior frontal gyrus (β=0.18, 
t(6,55)=2.34, p=0.02), and middle frontal gyrus (β=0.16, t(6,55)=1.98, =0.04) (Figure 4B). Model results 
are included in the supplemental table. 
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Figure 100 Race dependent connectivity to biomarker relationships. A) Amyloid burden and 
functional connectivity in the left hemisphere between the Apu and superior and middle frontal gyri. Line 
color indicates region. Dashed line indicates race, solid line indicates NHW. B) Amyloid burden and 
functional connectivity in the right  hemisphere between the Apu and superior and middle frontal gyri.   
Solid line indicates African American, dashed line indicates NHW. Grey background indicates a 95% CI. 
C) Regional WMH load in the left hemisphere between the middle and superior frontal gyri. Line colors 
indicates regions, Solid line indicates African American, dashed line indicates NHW. D) Regional WMH 
load in the right hemisphere between the middle and superior frontal gyri. Line colors indicates regions, 
Solid line indicates African American, dashed line indicates NHW. E) Summary figure of race dependent 
relationships. AA = African American, NC = normal cognition, WMH= white matter hyperintensities.  
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4.4 Discussion 
In this study, we found that fronto-putaminal functional connectivity is independently associated 
with AD and WMH. Connectivity between APu and its cortical inputs (pre-/post-central gyrus) were 
related to clinical and biochemical markers of AD.  Effects of AD further extended to connections linking 
APu with its cortical outputs (superior/middle frontal gyrus) only in African Americans, with opposite 
relationships between WMH and connectivity in these regions between African Americans and NHWs. 
These findings are consistent with our previous report that African Americans and NHWs may show 
opposite patterns of brain connectivity change in parts of the brain but not others.   
Prior studies have highlighted altered white matter track integrity between the putamen and its 
cortical inputs (post and pre central gyri) or outputs (middle and superior frontal gyri) (Purves, D et al., 
2001) in dementia. Within vascular dementia, the putamen exhibits atrophy and impaired white matter 
tract integrity 232. In early stages of AD (e.g., subjective cognitive complaints and mild cognitive 
impairment stages), the putamen and frontal lobe also exhibit impaired white matter integrity which 
correlates with increased amyloid burden101,248 and decreased regional cerebral blood flow 249.  One may 
thus expect APu-related connectivity to decrease over time, consistent with current models of decreased 
DMN connectivity in AD66,150 211. However, DMN connectivity includes both long and short range brain 
connections and is a conglomeration of multiple white matter tracts 250. If networks simplify in the 
presence of disease, connectivity between nodes may actually increase198.  Indeed, we previously 
observed increased connectivity in certain parts of the DMN among African Americans with AD 211. In 
the current work, increased connectivity between the APu and pre/post-central gyrus with more 
pathologic CSF Aβ42 for both races may also exemplify this phenomenon.  Thus we do not interpret this 
increase in cortical input to APu as strictly pathological or compensatory at this time. It is therefore not 
straightforward to reconcile our findings with white matter tract analysis. 
We also used a novel method to quantify WMH in the APu and its cortical connections impacted 
in AD.  WMH is found commonly in AD and vascular dementia, and their presence in those with vascular 
risk factors but no neurological symptoms further complicates their interpretation in 
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neurodegeneration102,103,251. A region-specific approach to WMH analysis may better identify the 
pathologic process in that anatomical context, but regional analysis has broadly included qualitative or 
semi-quantitative distinction between deep vs peri-ventricular, anterior vs posterior, cortical vs. 
subcortical, and lobar vs. Brodmann area102,250.  Building on the APu connectome, we were able to 
directly test whether WMH at APu network nodes influenced the inter-nodal connectivity within and 
across individuals. In this case, a negative association between nodal WMH and inter-nodal connectivity 
(e.g., right Apu-pre/post-central gyrus) supports the pathological role of nodal WMH, but a lack of 
association (e.g., right APu-superior/middle frontal gyrus) does not rule out the importance of WM tract 
abnormality.  Importantly, the distinct effects of greater plaque burden (more pathologic CSF Aβ42) and 
WMH on all but one APu-related connectivity examined do not suggest WMH in the APu network to 
reflect AD-related pathology, even if posterior peri-ventricular WMH has been found to more associate 
with AD pathology than anterior peri-ventricular WMH.    
APu-superior/middle frontal gyrus connectivity was the one measure which differed between 
African Americans and NHW.  The left APu-cortical connectivity also showed the same direction of 
change between AD and WMH in African Americans.  Although our analyses did not reveal a 
mechanistic explanation for the underlying connectivity differences, as connectivity values were not 
related to hypertension, presence of type-2 diabetes, or socioeconomic status, the magnitude and 
consistency of regions across hemispheres in which African Americans exhibited lower connectivity 
should not be discounted. Potential explanations of the underlying connectivity differences include 
dietary and lifestyle habits, brain-specific inflammatory responses 146, environmental and other exposure 
associated with poverty  252 and stress associated with social and racial inequity 207. In animal and human 
neuroimaging studies, stress does seem to exert regional influence on fronto-striatal circuitry, particularly 
the middle and superior frontal gyri253–255. The stress of perceived racism, and additional relevant 
biological and environmental disparities that exist within the African American population could 
predispose these regions to AD pathology, but more research on life stressors would be necessary to draw 
this conclusion126,256.  It is well recognized that standard predictors of disease progression such as 
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cognitive function and hippocampal volumes fall short in determining the rates of cognitive decline in 
African Americans113.  Limited multi-racial studies have suggested WMH to better track dementia 
progression in African Americans than in NHW113, yet many studies continue to exclude individuals with 
vascular disease or under-recruit minorities including African Americans.  This study reiterates the 
importance of including individuals with vascular disease in AD research, especially those with greater 
prevalence of vascular disease as well as greater incidence of dementia.   
This study has a number of limitations. We recruited more participants with NC and MCI than 
AD dementia, thus focusing our work on brain changes in older individuals without severe impairment at 
the expense of generalizability. Future research with increased AD dementia participants as well as 
longitudinal changes in WMH and AD pathology is necessary to validate the patterns we described.  The 
cognitive measures utilized were not consistent across cohorts. Although Z-transformation controlling for 
cohort effect did yield significant connectivity-to-cognition relationships, casting a more extensive 
neuropsychological battery across all cohorts would extend the region-specific analysis to also cognitive 
functions.  Amyloid and tau PET imaging was not performed in these subjects.  Even though CSF Aβ42 
levels closely correlate with global amyloid PET measures, the latter may provide higher resolution 
characterization of AD pathology in a region-specific manner257.   
Conclusion 
In this study, we intended to determine whether AD affected putaminal connectivity. We 
identified the pre and post central gyrus within a network vulnerable to AD independent of race, and the 
superior and middle frontal gyrus within a related network displaying race-specific associations with AD.  
Connectivity was increased or showed no change in AD among NHW participants, but decreased more 
often than increased in African Americans.   
These findings along with our previous work highlight that functional connectivity, like other 
intermediate measures of neurodegeneration, is not a linear metric of AD pathology or WMH.  It provides 
a dynamic profile of neurodegeneration, and region- and context-specific changes likely have pathologic 
correlates which need more detailed confirmation.  AD pathology appears to have a more consistent 
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connectivity profile between APu and its cortical inputs across races, with AD and WMH demonstrating 
different patterns of interaction between older African American and NHW participants.  This work is in 
line with previous research recommendations that considering amyloid, tau, or cognitive decline without 
WMH is insufficient for a functional profile of older individuals, yet treating WMH as a uniform measure 
of either AD or vascular disease according to qualitative divisions (e.g., anterior vs. posterior) likely 
undermines its pathologic significance.  Future experimental studies should focus on elucidating 
pathologic substrates which can selectively increase or decrease connectivity involving that region, and 
connectivity measures in these areas simultaneously vulnerable to AD, vascular injury, and neuro-
inflammation can then be used to identify the WMH etiologies. 
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4.5 Chapter 4 Tables 
 
  
Table 5 Combined demographic variables for all participants across cohorts. SD = standard deviation. M= male, 
F= female. MCI = mild cognitive impairment, AD = Alzheimer’s disease. 
 Normal Cognition 
(N=187) 
MCI (N=53) AD (N=27) 
 AA (n=95) NHW 
(n=92) 
AA (n=27) NHW (n=26) AA (n=8) NHW 
(n=19) 
Age 
mean(SD) 
62.96 (9.29) 65.65 (9.15) 69.38 (7.88) 72.06 (6.36) 70.13 
(10.34) 
68.86 (8.63) 
Gender 
%M/%F 
21.05/78.95 45.65/54.35 44.44/55.56 46.15/53.85 37.50/62.50 47.37/52.63 
National 
Area 
Deprivation 
Index 
mean(SD) 
50.83 
(24.10) 
33.12 
(21.99) 
51.69 
(23.18) 
32.12 
(20.73) 
59.83 
(32.08) 
35.38 (21.71) 
State Area 
Deprivation 
Index 
mean(SD) 
4.40 (2.56) 2.85 (2.10) 4.38 (2.53) 2.28 (1.49) 5.67 (3.27) 2.94 (1.73) 
Hypertension 
% have 
50.53 34.78 77.78 57.69 75.00 31.58 
Type-2 
Diabetes % 
have 
10.53 4.35 22.22 15.38 25.00 21.05 
Cognitive Z 
score  
Mean (SD) 
0.05 (0.92) 0.14 (0.81) -0.66 (0.58) -0.87 (0.80) -2.26 (1.12) -2.26 (0.70) 
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Table 6 Demographics stratified by cohort. AA = African American, NHW = Non-Hispanic White, SD = 
Standard Deviation.  
  
 Cohort 1 (N=66) Cohort 2 (N=113) Cohort 3 (N=88) 
 AA (n=24) NHW 
(n=42) 
AA (n=52) NHW 
(n=36) 
AA (n=54) NHW 
(n=59) 
Age 
mean(SD) 
69.27 
(7.82) 
70.03 
(6.57) 
58.49 
(8.34) 
58.58 
(6.55) 
68.92 
(7.68) 
71.00 (7.87) 
Gender 
%M/%F  
25.00/75.00 45.24/54.76 15.09/84.91 50.00/50.00 39.62/60.38 44.07/55.93 
National 
Area 
Deprivation 
Index 
mean(SD) 
47.83 
(23.85) 
27.95 
(19.25) 
53.19 
(21.17) 
37.11 
(23.19) 
51.35 
(27.47) 
34.65 (21.79) 
State Area 
Deprivation 
Index 
mean(SD) 
4.13 (2.52) 2.26 (1.43) 4.60 (2.24) 3.22 (2.26) 4.48 (2.97) 2.82 (2.04) 
Hypertension 
% with it 
62.50 30.95 43.40 33.33 69.81 47.46 
Type-2 
Diabetes % 
with it 
20.83 7.14 3.77 0 20.75 15.25 
Cognitive Z 
score  
Mean (SD) 
-0.06 (1.15) -0.08 (1.02) 0.07 (0.99) 0.02 (1.02) -0.66 (0.94) -0.87 (1.18) 
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Table 7 Coefficients for diagnosis, cognition, and racial differences and connectivity between the 
left and right anterior putamen and other regions of interest. 
 
 
  
Left Anterior Putamen 
  Diagnosis Cognition 
Lower in AA with 
NC 
  B t p B t p B t p 
Precentral 
Gyrus 
-0.07 -0.81 0.42 0.13 1.65 0.05 0.13 2.28 0.02 
Postcentral 
Gyrus 
-0.07 -0.78 0.43 0.14 1.79 0.05 0.06 1.05 0.29 
Superior 
Frontal 
Gyrus -0.05 -0.25 0.8 -0.03 -1.43 0.15 0.1 2.09 0.03 
Middle 
Frontal 
Gyrus -0.12 -0.56 0.58 -0.01 -0.58 0.56 0.14 2.81 0.01 
Posterior 
Putamen 0.12 0.56 0.57 0 0.03 0.98 0.04 0.8 0.43 
Caudate 0.18 0.09 0.93 0 0.05 0.96 0.02 0.04 0.66 
Insula 0.07 0.34 0.73 -0.02 -1.01 0.31 0.08 1.52 0.13 
Right Anterior Putamen 
  Diagnosis Cognition 
Lower in AA with 
NC 
  B t p B t p B t p 
Precentral 
Gyrus 
0.13 1.65 
0.0
5 
0.04 1.7 0.04 0.07 1.23 0.22 
Postcentr
al Gyrus 
0.14 1.79 
0.0
5 
0.05 2.21 0.03 0.06 1.09 0.28 
Superior 
Frontal 
Gyrus -0.07 -0.31 
0.7
6 -0.02 -1.39 0.16 0.12 2.27 0.02 
Middle 
Frontal 
Gyrus -0.12 -0.64 
0.5
2 -0.02 -1.02 0.31 0.13 2.3 0.02 
Posterior 
Putamen 0.11 0.47 
0.6
4 -0.01 -0.66 0.51 -0.01 -0.11 0.91 
Caudate -0.21 -0.93 
0.3
5 0 -0.36 0.72 0.05 0.96 0.34 
Insula 0.1 0.45 
0
.66 -0.02 -1.22 0.22 0.04 0.91 0.36 
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5 CONCLUSION 
In the following sections we integrate our findings across aims. We first introduce our research questions 
and a summary of related findings. We then discuss findings that are not dependent on race within the 
DMN and the putamen and integrate these findings across networks. This is followed by a discussion of 
race dependent findings in both the DMN and cortical output putamen nodes, and how these biomarker to 
connectivity relationships inform our understanding of AD within AAs. We then review the role, or lack 
thereof, of WMH in explaining these relationships, and review other potential explanations for our 
findings. We conclude with a discussion of race and how this study answers, but also poses a variety of 
questions related to how we should operationalize race in future research.  
5.1 Research Questions 
The following section includes our research questions as well as a summary of the findings for 
each question.  
Do African Americans have different connectivity to AD biomarker relationships than NHWs 
within the DMN and its subnetworks? 
African Americans exhibit a connectivity profile different from that of NHWs. Contrary to NHW 
models, precuneus and posterior cingulate connectivity to regions of the dorsomedial subsystem 
increases as disease burden increases.  
Does putaminal connectivity relate to AD biomarkers?  
Connectivity between cortical inputs and the anterior putamen correlates with Alzheimer’s 
disease burden such that as CSF Aβ42 decreased, connectivity between the anterior putamen and 
pre and post central gyri increased. In the right hemisphere, as cognitive performance decreased, 
connectivity increased in these same regions.  
Does race modify these relationships between putaminal connectivity and AD biomarkers? 
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In the data from the African American participants, as CSF Aβ42 decreased, connectivity 
between the anterior putamen and the superior and middle frontal gyri also decreased.  
Do hyperintensities in the DMN and in the putamen networks explain the observed racial 
differences? 
In our sample, hyperintensities in the DMN did not explain the significant race X Aβ42 
interaction for DMN connectivity, and did not account for the racial group differences in 
connectivity that we observed between APu and superior and middle frontal connectivity. 
However, regional hyperintensities within the putamen and these cortical output regions was 
related to connectivity in the left hemisphere in African Americans, such that as regional WMH 
burden increased, connectivity also decreased.  
5.2 Integrating race independent connectivity associations with AD biomarkers 
 We identified a number of regions for which the relationships between connectivity and AD 
biomarkers were consistent across racial groups. In the DMN, these measures include connectivity 
between regions of the medial temporal lobe subsystem and between the midline core and medial 
temporal subsystems such that as CSF t-Tau increased, connectivity also increased. Within the putamen 
network, the consistent measures include connectivity between the anterior putamen and the pre and post 
central gyri. Within these regions, as disease burden (measured by the particular biomarker) increased, 
connectivity also increased. Typically individuals with a higher AD burden exhibit lower connectivity 
between DMN regions, but results are inconsistent in the putamen64,258. The increased connectivity that 
we observed within the DMN may be driven by the relatively larger group of individuals with MCI 
compared to AD. Because an increase in connectivity is often observed in MCI59, and many studies 
consider diagnostic categories instead of continuous biomarker measures, and only a few studies have 
examined DMN subnetworks in AD259,260, our results may not directly map onto previous studies. 
However, because the DMN subnetworks have unique functions measures (i.e. MTL correlates with 
memory and midline core is responsible for self-reflection)62, and do not exhibit uniform relationships 
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with biomarkers as observed in the first aim, we recommend utilizing these subnetworks in future studies 
investigating DMN connectivity and continuous relationships with biomarkers.  
Connectivity between the anterior putamen and its cortical input nodes (pre-post central gyrus) 
were related to both cognition and amyloid. The hyperconnectivity that we observed could be a 
pathological response to disease presence, or functional compensation as other regions begin to succumb 
the effect of AD. These particular measures of connectivity were independent of race, and thus we would 
recommend them as ROI’s in future studies in diverse cohort. If others achieve replication of our results 
within this network, we could then recommend that this network be a preferred network of study in 
samples with diverse of individuals across the disease spectrum of AD. A previous EEG study identified 
hyperexcitability in the presence of AD within the sensorimotor cortex261, despite the fact that this region 
is relatively spared from atrophy. This finding highlights an advantage of functional connectivity 
approaches, as it can examine complex neurological interactions beyond cell death. A summary figure of 
the race independent relationships is included below.   
 
Figure 111 Summary figure of general race independent relationships between increasing disease 
burden as measured by AD biomarkers. Green line indicates the DMN MTL functional connectivity. 
Yellow indicates pre and post central gyri connectivity. DMN MTL = Default mode network medial 
temporal lobe, APu = anterior putamen.  
 
This works gives partial support to the amyloid hypothesis in that it is initial amyloid deposition 
that starts the dementia cascade. The DMN, the first network to be affected in the course of AD was 
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related to both CSF tau and amyloid58. However, the putamen and its cortical nodes were not related to 
tau, but more consistently related to amyloid. According to Braak staging, the frontal lobe is affected later 
in the course of disease199. The amyloid hypothesis states that amyloid build up causes a metabolic 
cascade that eventually leads to tau deposition, but precedes NFT’s by many years24. Atrophy typically 
correlates more strongly with tau, as the NFTs are what may trigger cell death. Amyloid buildup may 
signal the first stages of AD, and generate some of the functional changes that can be observed in fMRI 
studies. The consistent amyloid relationships that we identified in the putamen analyses could also reflect 
the overall impact of amyloid even in normal aging, as amyloid plaques are fairly common even in 
individuals with intact cognition. Further research would benefit from amyloid PET262 studies that 
identify whether regional amyloid buildup in the putamen network we describe relates to connectivity.  
The fact that tau was related to DMN MTL connectivity, but not to fronto-putaminal connectivity 
is in line with previous literature168. We would likely see significant relationships between tau and 
connectivity in a larger set of individuals in the later stages of dementia. Amyloid emerges earlier, and 
our cohort did have early MCI and individuals with NC. Based on Braak staging, frontal regions are not 
typically inundated with tau until later in the disease199, and our cohort did have a larger proportion of 
controls. It is likely that some of these individuals had amyloid deposition, but had not, or will never cross 
the threshold into the Braak stages of tau deposition in the frontal areas. Further tau-pet45 studies of 
individuals with MCI and AD should investigate these regions to determine if regional tau deposition may 
correlate with connectivity in the putamen nodes that we identified.  
We identified relationships with cognition and connectivity in both of our networks of interest. 
Although related inversely to connectivity within NHWs for our DMN measures, it is important to 
recognize that connectivity measures were related to cognition in Cohort 3, which included individuals 
across the dementia spectrum, including AAs with AD, and related to a variety of connectivity within the 
DMN between the midline core and dorsomedial subsystems. Within the putamen network, cognition 
correlated with connectivity measures in the right hemisphere, between the right anterior putamen and the 
right pre and post central gyri. The lack of many significant relationships between cognition and 
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connectivity identified between the putamen and network regions could be a result of the fact that our 
sample for the putamen connectivity analyses included a larger group of individuals who were younger 
and had normal cognition. Our findings could indicate that amyloid exerts greater influence on 
connectivity without much relationship to cognition in this putamen network particularly earlier in the 
stages of AD or eventual AD153. Before cognitive symptoms emerge, amyloid could exert influence on 
connectivity, in a variety of regions including the putamen and its cortical nodes, but connectivity in these 
regions may not exhibit relationships with cognition and tau until much later in the disease263. An 
alternative explanation could be that the cognitive tests utilized in these cohorts are better at detecting 
memory impairment than impairment in other cognitive domains. The cognitive scores utilized in the first 
aim were taken from an extensive cognitive battery, but the other cohorts only had the MMSE and the 
MoCA. While the MoCA is more sensitive to cognitive domains for which the putamen and the cortical 
nodes are responsible (motor and visual spatial impairment)52, utilizing a different cognitive measure for 
each cohort likely introduces noise that obfuscates relationships between cognition and putamen 
connectivity, especially given the cultural bias associated with these assessments that often over-predicts 
cognitive impairment in African Americans264. Future studies will investigate individuals with MCI and 
AD to determine whether putamen connectivity does indeed exhibit relationships with tau and cognition 
and whether these alterations manifest in cognitive performance, and investigate the relationships 
between cognitive domains outside of memory and the relationship to putamen connectivity. 
5.3 Race Dependent relationships with AD biomarkers 
Current consensus drawn from functional, structural, and pathological studies is that the 
hippocampus and the DMN are the primary regions affected by Alzheimer’s Disease59. While research of 
these areas has yielded a wealth of scientific findings with clinical utility, there are many questions about 
the etiology and disparities within AD that may be answered by broadening the scope beyond the DMN 
and hippocampus. The DMN has been thoroughly explored in AD, and results across studies with similar 
definitions of the DMN, and similar methodological approaches have fairly consistent findings indicating 
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that DMN within network connectivity is lower in individuals with AD compared to NC, and declines as 
the disease progresses59. This work adds to the current body of literature by replicating previous studies 
and that use the DMN subnetwork connectivity measures in our sample of NHWs, and providing 
measures that may be sensitive to the biological changes generated by diverse ethno-cultural 
backgrounds.  
Our findings within the NHW sample support previous literature that, within this group, DMN 
connectivity typically declines as AD burden increases. Our data-driven ICA approach to identifying 
components of the DMN, rather than utilizing seed-maps, could have been responsible for the increases 
we observed in AA, in that our data driven component maps perhaps did not represent the established 
DMN regions. However, because we identified the typical pattern of AD-related connectivity decline in 
NHWs, we can be fairly certain our methodology choice does not account for the disparate connectivity 
to biomarker relationships that we observed.  
 
African Americans are less likely to exhibit amnestic profiles than their NHW counterparts; they 
have slower cognitive and functional decline, and different predictors of cognition. These facts 
compounded with evidence for a unique functional profile point to a possible sub classification of 
Alzheimer’s disease that includes a consideration of lifestyle and genetic risk factors. Some papers 
suggest that MCI is characterized by a temporary increase in DMN connectivity, followed by the gradual 
decline associated with AD. AAs in our sample could be exhibiting an extended MCI-like connectivity 
profile. The diagnosis of AD within AA could be generated by a lower level of pathology, yet is 
exacerbated by comorbidities such as vascular disease.  This may seem counter intuitive, but it suggests 
contributing comorbidities extant in AAs cause AD symptoms to emerge with a much lower pathology 
burden than in NHWs. This also may contribute to their greater life expectancy as the AA phenotype of 
AD may not be as severe, and may be more attributable to other neurological burdens. These results 
would be in line with other studies that have identified slower rates of cognitive decline in African 
Americans109, and these connectivity increases could be an extension of this MCI hyperconnected phase. 
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Further studies investigating a greater number of AA individuals with AD would be necessary to explore 
this hypothesis.  
In Alzheimer’s disease, the hippocampus is typically included in default mode network analyses155. 
The DMN supports self-referential cognitive processes, including memory. Lower functional connectivity 
between DMN regions typically correlates with worse general cognition, higher AD burden, and worse 
memory performance63. Our findings from the first aim provide a neurological basis for the increased 
prevalence of non-amnestic MCI in African Americans and possibly explain why cognitive decline tends 
to progress more slowly in African Americans. Cognitive assessments tend to rely heavily on working 
memory265. The MMSE and MoCA both include at last one question that relies on memory, and lower 
working memory capabilities can impair assessment performance even on questions designed to assess 
visuospatial abilities. MoCA is more sensitive to detecting cognitive impairment other than memory, but 
both of these assessments are most commonly used to detect Alzheimer’s disease265. Cognitive tasks that 
specifically assess motor function may be more sensitive to AD detection in African Americans as a result 
of underlying vulnerable region.  
African Americans exhibited decreased connectivity between the APu and superior and middle 
frontal gyrus as CSF Aβ42 decreased. It is possible that the hyperconnectivity between the cortical input 
regions and the APu that we observed is a form of functional compensation for connectivity decline in 
other brain regions. We observed a decline in connectivity between DMN nodes in NHWs as AD burden 
increases, and between APu and superior and middle frontal in AAs (Figure 11). In individuals with 
normal cognition, African Americans exhibited lower connectivity between the anterior putamen and the 
superior and middle frontal gyrus. This finding, coupled with the increase in connectivity between the 
putamen and the pre and post central gyrus across races suggests that while there are uniform 
relationships between AD pathology and motor-putamen circuits, downstream frontal regions may be 
preferentially affected by race.  
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Figure 122  summary figure of race dependent relationships between increasing disease burden as 
measured by AD biomarkers. Only relationships within African Americans are displayed in this figure. 
Green line indicates the DMN MTL functional connectivity. Yellow indicates pre and post central gyri 
connectivity. DMN MTL = Default mode network medial temporal lobe, APu = anterior putamen.  
 
We were not able to identify any variables that fully accounted the differences in biomarkers 
across racial groups. Many of the variables typically entangled with race, such as socio-economic status, 
hypertension, and white matter hyperintensity volume did not account for the effect of race on the 
biomarker to connectivity relationships in the DMN or in the putamen. Explanations for our findings 
could be a result of a complex interplay of biological and sociological factors whose measurement was 
outside the scope of this study. African Americans in these samples on average had lower socioeconomic 
status as measured by the ADI. However, including ADI in our analyses did not account for the 
significance of interaction terms. It is possible the ADI serves as a crude measure of SES, as it is merely a 
snapshot of where an individual resides at a particular time, and that is not the only factor entangled with 
race that may explain these racial differences. Low socio-economic-status266 and perceived racial 
discrimination, both commonly reported in AAs205, can affect the brain throughout the developmental 
spectrum. These factors create decreased connectivity across large scale brain networks that could create 
reliance on small scale networks267, and these connections would then be reinforced over time. This could 
create a functional connectome that relies heavily on a functionally segregated, rather than integrated, 
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networks.  Resilience to negative outcomes associated with challenging life events is associated with 
increased connectivity between the sensorimotor cortex and the putamen, a phenomenon that we observed 
in both races, though unrelated to resilience268. The slow decline observed in African Americans could be 
a result of the fact that previous reliance on small scale networks would be less impacted by Alzheimer’s 
disease than NHWs, and that our NHW cohort exhibits functional integration that declines in response to 
disease. This could explain the slow decline exhibited by African Americans, as the networks would 
already be organized into functionally segregated networks, and the presence of disease may just enhance 
this underlying network structure. However, in NHWs in our sample, cognitive function would be 
primarily reliant on functional integration, and a disruption in this integration caused by AD pathology 
would lead to segregation and force networks to reorganize at a more rapid pace. A graph theoretical 
approach, particularly of longitudinal data, would allow us to test these hypotheses.  
5.4 WMH and DMN connectivity 
Our hypothesis that regional WMH within the DMN explained the significant effect of race on 
connectivity and biomarker relationships was not supported. WMH within these regions were not related 
to connectivity, and did not account for the significant race interaction term. However, this finding is not 
conclusive, and warrants further exploration in a larger dataset. Our cohort that included the connectivity 
and WMH data was not the same cohort used for our Aim 1 analyses. There were less participants in the 
WMH dataset, and we did not identify identical relationships between biomarkers and connectivity within 
this dataset. This is likely that we were underpowered to detect an effect, and that our cohorts had a 
different diagnostic distribution. In our WMH analysis dataset, we did not have any AAs with AD, only 
NC and MCI, but we did have NHWs across all diagnostic categories. Furthermore, the cognitive data 
from this cohort was limited to one general measure of cognition rather than from a battery of 
neuropsychological tests.  
We did not identify regional differences between AA and NHW in WMH volume within the 
tracts of the DMN regions that we investigated. These DMN subsystem WMH volumes were not related 
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to CSF Aβ42 or CSF T-tau, even when we only utilized data from individuals with MCI and AD. If we 
did identify a significant relationship between CSF biomarkers and regional WMH volume, it would 
support the notion that WMH in these regions may be caused by AD pathology. However, our results do 
not support this hypothesis. Our findings are not conclusive, as we had a relatively small sample size (23 
individuals with some form of cognitive impairment), and of those individuals, only 10 had 
corresponding CSF data. It is likely that we were underpowered, and a larger sample size would be 
necessary to detect a significant relationship between WMH and CSF biomarkers, especially given the 
differences in CSF T-tau levels between NHW and AAs.  
WMH within the default mode subnetworks did not mediate the race by biomarker interaction 
terms. This finding should not be taken as conclusive evidence that WMH do not play a role in DMN 
connectivity. We were not able to replicate same race and biomarker interactions that we identified in the 
cohort of our first aim. This is likely a result of the limited distribution of our sample across race and 
diagnostic categories. However, previous studies do support these findings. Studies have inconsistently 
identified a relationship between amyloid and WMH, and between tau and WMH99,102,269. Many of the 
studies that correlate tau with WMH do so at a pathological post-mortem level, and identify WMH based 
on pathology rather than MR imaging. Little research exists that probes the mechanistic relationship 
between tau and WMH, and without longitudinal models, it will be difficult to establish a causal 
relationship. However, as tau-pet becomes more widely used, answering this question will become more 
feasible.  
5.5 WMH and Putamen Connectivity  
This work illustrates the importance of considering not only racial groups in analyses of 
individuals with AD, but comorbidities. Ruling out individuals who have contributing comorbidities may 
be appropriate to generate models that specifically study mechanisms related only to AD, but if other 
comorbidities are in fact risk factors for the disease being studies270, the synergistic mechanisms between 
the disease of study and the comorbidities will be largely ignored. This research emphasizes the important 
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role of the contributing factors of vascular insult in the form of small vessel disease, as represented by the 
presence of WMH in the brain. Because we identified WMH burden in many controls in the absence of 
elevated amyloid beta, WMH may be generated ahead of amyloid burden, and not directly caused by ad 
pathology. This WMH does play a role in decreasing basal ganglia function particularly in AAs, which 
manifests as lower mid and superior connectivity. It is likely that in fronto-putamen regions, WMH 
increases susceptibility to the effects of Aβ42, rather than Aβ42 generating WMH. This finding adds to 
the hypothesis that AD related WMH are located in more posterior and temporal regions101 rather than 
frontal and subcortical WMH, which seem to be more vascular in nature271. This work also adds to the 
hypotheses that WMH can disrupt pathways not only along tracts, but also within nodes65. Current 
research is limited to tract specific findings, but this work demonstrates that nodal WMH can also 
influence functional connectivity, particularly in metabolically active areas sensitive to oxygen and 
nutrient deficits.  
The putamen and thalamus are regions particularly vulnerable to ischemic changes272. Metabolic 
studies indicate that these regions are highly metabolically active. This increased metabolic activity would 
make them particularly susceptible to the oxygen and nutrient deficits generated by ischemia and small 
vessel disease273.  However, it is not likely that putamen WMH are the cause of the connectivity 
relationships we identified as being related to AD. In this work, we identified what regions exhibit 
connectivity changes related to AD, and those related to WMH. These two factors likely have a 
synergistic effect on connectivity, with African Americans exhibiting greater susceptibility to WMH. 
Why AAs exhibit this vulnerability remains unclear.  
The current work supports the notion that amyloid burden is not related to WMH etiology. Within 
the amyloid literature, the relationship between WMH and amyloid is also controversial. The evidence 
that amyloid and WMH have a causal relationship is weak, and many studies have found no relationship 
between the two biomarkers even across different modalities of amyloid measurement (amyloid pet, 
amyloid staining, and CSF amyloid).  
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5.6 Limitations & Future Directions 
Our findings should be considered in context of this work’s limitations. We did not have uniform 
measures across all participants. Our cognitive measures were different across the three cohorts, and we 
did not have regional WMH for all participants. We were able to identify consistent relationships between 
connectivity and cognition across the cohort despite this limitation, but the extensive cognitive battery 
with standardized scores as we have for cohort 2 would obviously provide more accurate measures of 
cognition that would not exhibit the racial bias evident in more general tests of cognition. The lack of AA 
individuals with AD in the WMH limits the generalizability and validity of our findings such that we 
cannot fully overlay our functional relationships identified in Aim 1 on our WMH results. Future analyses 
will explore regional WMH and connectivity in a larger cohort with particular emphasis on a larger 
number of AA individuals with AD. 
Our analyses were limited to studying race and biomarker interaction terms, and considering the 
effects of gender were outside the scope of this study. In addition to race, gender also has biological and 
social definitions. Disparities exist between genders such that women are more likely to develop AD274, 
but live longer than men with AD. Studying the impact of intersectionality in Alzheimer’s Disease can 
widen the net of individuals with whom clinicians should consider at risk for AD and allow for more 
targeted public health campaigns and interventions to address some of the modifiable factors of AD that 
may be entangled with these social and biological categories.  
Although we were able to include a large percentage of AA individuals across our cohorts, we did 
not have a sufficient number of AA individuals with AD to completely replicate our findings from Aim 1. 
While we did identify some consistent relationships across cohorts in cohort 1, a larger sample of AA 
individuals with AD would be ideal to determine the generalizability of our results. While this work does 
establish biological manifestations of health disparities, there are a number of biological and sociological 
factors that we did not consider that may play a role in the manifestation of these disparities. As 
previously mentioned, the sociological aspects of race, while socially constructed in nature, can generate 
disparate health outcomes. For example, perceived racial discrimination205, lower socio-economic 
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status275, education quality276, and residential environment during childhood252, family and community 
bonds, and resilience277, all of which show differences across racial groups, can have negative and 
protective effects on brain health. Our sample of African Americans should in no way be taken as 
representative of all African Americans. A nuanced approach of examining the aforementioned variables 
should be the focus of future analyses, rather than broad categorization of individuals based on race. 
However, in order to increase participation of individuals of diverse in science studies and make the case 
for national investment of funds in this effort, establishing gross racial differences is the first step. 
The only measures of pathology that we used were derived from CSF. While this is useful in 
determining the validity of our connectivity measures and whether they are related to gross levels of CSF 
tau and amyloid, it would be valuable to investigate the regional distribution of tau and amyloid through 
PET scans, and whether regional distribution of these pathologies are related to connectivity and regional 
WMH. This would enable us to more accurately add to the WMH etiology debate, and determine how 
these pathologies may affect connectivity, i.e. are tau and Aβ42 within the DMN generating functional 
connectivity changes, or is the DMN responding to amyloid and tau deposition elsewhere is the brain.  
This study used cross-sectional data across the disease spectrum to understand how biomarkers 
and connectivity are related to one another at varying levels of disease burden. However, to uncover 
casual mechanisms and develop disease trajectories that may be specific to a particular race, longitudinal 
models would be necessary. We modeled the biomarker and connectivity relationships using linear 
functions, as that is the simplest and most logical place to begin an analysis. However, our understanding 
of how CSF biomarkers change over the course of the disease is limited, particularly within African 
Americans. The relationship between CSF Aβ42 and connectivity could be stronger in the earlier phases 
of the disease, and then plateau as the amyloid threshold for the development of AD is reached37. While 
this can be modeled in a cross sectional analysis, a longitudinal analysis would provide more sensitivity to 
track changes across disease development, and we can adjust current disease trajectory models to include 
race, and introduce regional staging of functional connectivity changes. We would also like to confirm 
that WMH emerge before functional connectivity changes using a longitudinal model, and whether CSF 
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tau and amyloid alterations in the CSF occur before the emergence of WMH. While it seems logical that 
WMH could influence FC, we are still not sure whether the two variables are correlated or causally 
related. It also seems logical that WMH would be present before CSF and tau alterations, but that is under 
the assumption that WMH are not caused by AD pathology278. While this study suggests that WMH are 
independent of AD pathology, a longitudinal analysis would provide more conclusive evidence either 
way. 
This work brings into question the definition of race. Many people try to define race as a purely 
genetic concept193, but the lines between races from a purely genetic standpoint are nonexistent in the US 
at least. In fact, many NHWs in the U.S. exhibit similar genetic profiles to AAs279. This leads others to 
argue that race is purely a social construct with little biological utility11. The answer most likely lies 
somewhere in the middle, as this work can attest to. A failing of this work is that we have had to include 
African Americans as one group, when in fact “African Americans” are a diverse minority group with a 
variety of socioeconomic, genetic, and lifestyle backgrounds. The term “African American” obviously 
has some utility in the clinic, as African Americans do have higher prevalence rates of AD1. However, 
when we controlled for many of the factors that could potentially explain the racial disparities that we 
identified, such as presence of vascular disease, type-2 diabetes, socio-economic status, and risk genes, 
we still had significant racial differences that no variable fully explained. This work supports the notion 
that “race” in the context of Alzheimer’s Disease is more of a complex interplay between ethnicity, 
ancestry, and lifestyles, and that “ethno-cultural” group may more accurately describe the African 
American diaspora280. Furthermore, cohort effects may impact our results, as many of the older 
individuals in our studies grew up in a time of racial turmoil during or just after the conclusion of the civil 
rights movement276. While the current time leaves much to be desired in the area of race relations, the 
level of institutional racism present during the time of segregation and just after could create a lingering 
impression on brain health that cannot be captured by merely examining biological and lifestyle factors276. 
While we have to establish meaningful differences in order to encourage the inclusion of a diverse cohort 
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in future studies, we hope that in the future, more nuanced and precision approaches to quantifying ethno-
cultural backgrounds can be adopted.   
As this work conclusively shows, characterizing the functional profile of individuals with 
Alzheimer’s disease must be an inclusive process. A one-brain-fits-all approach doesn’t address the 
unique differences between sample populations. Even structural templates vary based on sample 
population, let alone functional connectomes with a larger number of variables. While we identified 
regions that did exhibit the same biomarker to connectivity patterns across races a number of these 
measures, particularly in the network most commonly studied in AD, we must carefully choose our 
regions of interest, and consider the makeup of our sample accordingly. Putamen input nodes seem to be 
consistently related to amyloid across races, while DMN connectivity should be considered with race as a 
variable of interest for analyses in cohorts that include African Americans and NHWs. If functional data 
is to be used as a biomarker for early detection of AD, or to predict conversion from MCI to AD, we must 
strive to create a profile that includes not just individuals from all backgrounds, but individuals who at the 
greatest risk of developing the disease.  
 .  
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